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ABSTRACT OF DISSERTATION 
BIOLOGICAL, BEHAVIORAL, AND PSYCHOSOCIAL ATTRIBUTES OF 
INDIVIDUALS WITH COPD 
The purpose of this dissertation was to evaluate the biological, behavioral, and 
psychosocial attributes of individuals diagnosed with chronic obstructive pulmonary 
disease (COPD). Specific aims were to: 1) explore the predictive power of spirometry 
measures for event-free survival in patients with heart failure and suspected COPD, 
focusing on the differences in survival between those with and without airflow limitation; 
2) examine the psychometric properties of the Multidimensional Scale of Perceived
Social Support (MSPSS) in patients with concomitant COPD and heart failure; and 3) test
the efficacy of a theory-based, multidimensional, self-care educational intervention using
an eHealth platform on measures of symptom severity and variability, anxiety and
depressive symptoms, perceived self-care ability, perceived self-care adherence, and self-
care information needs (knowledge) in a sample of adult patients with stable COPD.
Specific aim one was addressed by evaluation of the predictive power of 
spirometry measures (forced expiratory volume/second [FEV1], forced vital capacity 
[FVC], and the ratio of FEV1/FVC) for event-free time to combined 
hospitalization/mortality after controlling for clinical and sociodemographic variables. 
This analysis revealed that those patients with airflow limitation were 2.2 times more 
likely to experience hospitalization/mortality compared to those without airflow 
limitation. The second specific aim was addressed with a psychometric evaluation of the 
Multidimensional Scale of Perceived Social support (MSPSS) which included 
determination of internal consistency reliability, the factor structure and construct validity 
by hypothesis testing in participants with comorbid COPD and heart failure. The MSPSS 
was a valid and reliable instrument to measure perceived social support in patients with 
comorbid COPD and heart failure. The third specific aim was addressed by a trial of an 
eHealth educational intervention in participants with COPD (N = 20). This intervention 
resulted in significant change in symptom severity evaluation in patients categorized as 
having medium symptom severity for the following symptoms: distress due to cough, 
chest tightness, dyspnea with activity and fatigue; these symptoms were perceived as 
more severe in the intervention period. Anxiety, depressive symptoms and perceived self-
care ability were unchanged; however, perceived self-care adherence scores improved, 
and knowledge needs were significantly reduced after the intervention. 
KEYWORDS: Chronic Obstructive Pulmonary Disease, Self-Care, Self-Management, 
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CHAPTER ONE 
Introduction 
 Chronic obstructive pulmonary disease (COPD) is predicted to be the third 
leading cause of death worldwide by 2030.1 In the United States, 15 to 22 million people 
are currently diagnosed with COPD; the deaths from COPD are estimated to rise 30% in 
the next 10 years. 2,3 This disease is progressive, irreversible and characterized by 
persistent airflow limitation and respiratory symptoms.4 As COPD progresses, symptoms 
often become more severe, physical and psychological responses are elicited, and risk for 
hospitalization increases. Breathlessness or dyspnea is the most common symptom 
reported by those with COPD, followed by cough, troublesome mucous, wheezing, and 
chest tightness.5-10 Furthermore, approximately 40% of patients with COPD have clinical 
anxiety, and approximately 25% experience clinically significant depressive 
symptoms.11,12 Due to the high symptom burden and progressive nature of COPD, it is 
necessary for patients to perform a variety of self-care activities to maintain homeostasis. 
Self-care is defined as the process by which individuals with chronic disease 
attain optimal health through learned, intentional actions that include symptom 
recognition and response, adherence to prescribed treatment and medications, intentional 
lifestyle alterations, regular interaction with health care professionals, and evaluation of 
these actions.13 The increased incidence and prevalence of COPD has been the impetus 
for the development of education and training programs focused on development of 
effective self-care behaviors; these structured, and multi-faceted interventions aimed to 
educate, motivate, engage, and support patients to adapt their health behaviors and 
develop skills to provide relief of symptoms, slow the progression of disease, improve 
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physical functioning, improve health related quality of life and prevent exacerbations that 
require hospitalization. 4,14-17 Effective self-care for patients with COPD  improved 
health-related quality of life (HRQoL),15,18 reduced dyspnea,19 decreased risk for all-
cause hospitalization,19-21  and reduced anxiety and depressive symptoms.22,23 However, 
only 40% of patients with COPD demonstrate prolonged retention of self-care 
behaviors.24  
Consequences of poor self-care behaviors may result in quicker disease 
progression, increased morbidity and premature mortality; patients with COPD have an 
average life expectancy of 5.8 years less than age-adjusted healthy controls and are at 
70% to 90% increase likelihood of death if they have comorbid cardiovascular 
disease.19,25,26 However, self-care is a still a relatively new concept that has been 
understudied in this population. There is currently no consensus as to what constitutes 
appropriate self-care behaviors for patients with COPD; self-care behaviors taught to 
patients often vary from practitioner to practitioner,19,27 may not be evidence-based, and 
the patient’s pre-existing self-care abilities are not always taken into consideration.13 
Furthermore, studying patient self-care is particularly challenging in that patients spend a 
majority of time away from the healthcare setting, and researchers are often reliant on 
periodic self-reports of  patient subjective assessment of disease-state. Although there is a 
lack of research outlining standardized self-care recommendations, the consequences of 
performing self-care are clear; it is imperative that researchers develop and test 
standardized self-care interventions to promote sustainable self-care behaviors 
Traditionally, researchers used objective measures to gauge self-care efficacy and 
only recently have researchers begun to study the effects of self-care behaviors on 
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subjective outcomes such as HRQoL, perceived treatment adherence, perceived self-care 
ability and anxiety/depressive symptoms.19,21 Previous investigators concluded effective 
self-care for patients with COPD increased HRQOL by 5% – 6.5%15,18 and reduced 
anxiety and depression scores by an average of 2.7% to 18.4%.22,23,28 Moreover, findings 
and conclusions from a recent Cochrane review examining the benefits of self-care 
behaviors on outcomes further supported the effectiveness of self-care on outcomes such 
as HRQoL, anxiety, mortality and hospitalizations.19 Zwerink and colleagues concluded 
that the self-care interventions were effective at improving outcomes, however these 
investigators could not conclude which self-care behaviors were best at improving 
outcomes; tested self-care interventions were too heterogeneous.19 Although desirable 
outcomes resulted after implementing self-care interventions, there is a lack of evidence 
to support which interventions should be taught to patients with COPD; this reflects the 
current state of the science in self-care for patients with COPD. Additionally, there are 
limited research studies that evaluated the relationships between self-care and other key 
outcomes such as symptom burden, psychological distress, perceived treatment 
adherence, perceived self-care ability and self-care information needs (knowledge) in 
patients with COPD. Therefore, the purpose of this dissertation was to evaluate the 
relationship between the biological, psychosocial and behavioral self-care attributes on 
outcomes in individuals with COPD.  
Patients with comorbid COPD and heart failure share numerous commonalities 
such as the age of the affected population, cigarette smoking as a risk factor, presence of 
systemic inflammation, periodic episodes of disease exacerbation that require 
hospitalization, and dyspnea as a prominent symptom.29 Up to one third of patients 
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diagnosed with heart failure (HF) exhibit some degree of COPD, and approximately 40% 
of patients diagnosed with COPD have heart disease.30,31 Despite the high prevalence of 
comorbid disease and similarities in clinical presentation, the relationship of airflow 
limitation and combined all-cause hospitalization/mortality has not been explored in 
patients with heart failure. Chapter Two is a report of an analysis of spirometry measures 
made in patients with heart failure who were suspected to have comorbid COPD. This 
secondary analysis explored the predictive power of forced vital capacity (FVC), forced 
expiratory volume in one second (FEV1), and the ratio between the two (FEV1/FVC), for 
event-free survival in these patients. Cox proportional hazard modeling was used to 
examine the relationship between spirometry measures and all-cause 
hospitalization/mortality with and without adjusting for demographic and clinical 
covariates. Cox proportional hazards regression models compared all-cause 
hospitalization/mortality between those with and without airflow limitation. Those with 
airflow limitation were 2.2 times more likely to be hospitalized or die compared to those 
without (HR: 2.20, 95% CI 1.06 – 4.53, p = .03)  Those in New York Heart Association 
functional class III/IV were 73% more likely to have an event (HR: 1.73, 95% CI 1.00 – 
3.01, p = .05) when compared with those in NYHA class I/II. Patients who had never 
smoked were 62% (HR: 0.38; 95% CI 0.17 - 0.81, p = .01) less likely to have a health-
related hospitalization/death. 
Often, when pulmonary function decreases (indicating disease progression), key 
outcomes such as health related quality of life (HRQoL), functional capacity and 
cognition may also decline. As the disease progresses, it is common for patients to have 
caregivers, friends, family or significant others to help them manage their disease. 
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Chapter Three contains a psychometric evaluation of the Multidimensional Scale of 
Perceived Social Support (MSPSS) in a sample of patients with comorbid COPD and 
heart failure. The MSPSS measures perceived social support from friends, family, and 
significant others. The MSPSS was evaluated for internal consistency with Cronbach’s α 
and the split-half technique. Construct validity of the MSPSS was assessed with a factor 
analysis and hypothesis testing. The MSPSS demonstrated excellent internal consistency 
with Cronbach’s alpha consistently above .90. Factor analysis yielded a 3-factor solution, 
with items loading appropriately on the Friend, Family and Significant Other subscales. 
Hypothesis testing supported our hypothesis that higher levels of perceived social support 
predicted higher self-care management score (F [11, 291] = 2.463, R2 = .051, B = .151, p 
= 0.03). The MSPSS is a valid and reliable instrument to measure perceived social 
support in patients with comorbid COPD and heart failure.  
 There is a lack of evidence about the immediate effects of self-care interventions 
on key outcomes, particularly symptom burden (severity of distress due to cough, chest 
tightness, distress due to mucous production, dyspnea with activity, dyspnea at rest, 
fatigue, anxiety, and depressive symptoms). Chapter 4 reports a test of a theory-based, 
multidimensional, self-care educational intervention using an eHealth platform, on 
symptom severity and variability, anxiety and depressive symptoms, perceived self-care 
ability, self-care adherence, and self-care information needs (knowledge) needs in 
patients with COPD. Multilevel growth models were constructed to examine symptom 
severity and variability. Repeated measures analysis of variance examined the effect of 
the intervention on anxiety and depressive symptoms, and perceived self-care ability at 
the end of week 1, 2 and the conclusion of the reporting period. Paired t-tests determined 
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the effect of the intervention on perceived self-care adherence and self-care information 
needs (knowledge).  
Growth model analyses revealed that participants categorized as having medium 
symptom severity at baseline perceived the following symptoms as more distressful 
during the intervention period: distress due to cough (b = 10.16, 95% confidence interval 
[CI] 1.95 – 18.40, t(83) = 2.46, p = .02), chest tightness (b = 8.47, t[103] = 2.06, p = .04), 
dyspnea with activity (b = 13.18, t[82] = 1.97, p = .05), and fatigue (b = 16.48, t[134] = 
3.89, p < .01). However, those categorized as high severity at baseline reported 
significantly lower severity of chest tightness after the intervention (b = -8.15, t[113] = -
2.03, p = .04). There were no demonstrated effects of the intervention on symptom 
variability, anxiety, depressive symptoms or perceived self-care ability. However, there 
were improvements in perceived self-care adherence (baseline - 58.1 + 19.3, post 
intervention - 67.6 + 12.2, p = .025) and self-care information needs (knowledge) scores 
(baseline - 13.7 + 3.1, post intervention - 11.3 + 1.8, p = .012) after implementation of the 
intervention.  
Chapter Five concludes the dissertation with an overall summary of findings from 
the included manuscripts and the conclusions derived from these studies. Furthermore, in 
this chapter, implications for practice, as well as future directions for research in this 
population are proposed.  
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CHAPTER TWO 
Airflow limitation more than doubles the risk for hospitalization/mortality in patients 
with heart failure. 
 
Synopsis 
Comorbid chronic obstructive pulmonary disease (COPD) is found in 
approximately one third of patients with heart failure (HF). Survival in patients with 
COPD generally decreases as lung function declines. However, the association between 
lung function, hospitalization and survival is less clear for patients with HF. This 
manuscript reported a secondary data analysis about the predictive power of spirometry 
measures for the combined variable, hospitalization/mortality, in patients with HF. This 
analysis revealed that participants with airflow limitation were 2.2 times more likely to be 
hospitalized or die compared to those without airflow limitation. Those in NYHA 
functional class III/IV were 73% more likely to have an event when compared with those 
in NYHA class I/II. Patients who had never smoked were 62% less likely to have a 
health-related hospitalization/death. Thus, there is an increased need to screen and 
appropriately manage patients with heart failure and airflow limitation to reduce the risk 
for hospitalization/mortality. 
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Introduction 
Chronic heart failure (HF) and chronic obstructive pulmonary disease (COPD) are 
two of the top four causes of global mortality; HF and COPD account for approximately 
21.5 million deaths/year worldwide.1,32 Up to one third of patients diagnosed with HF 
also exhibit some degree of COPD, and approximately 40% of patients diagnosed with 
COPD have heart disease.30,31 HF and COPD share a number of commonalities that 
include the age of the affected population, cigarette smoking as a risk factor, presence of 
systemic inflammation, periodic episodes of disease exacerbation that require 
hospitalization, and dyspnea as a prominent symptom.29 Individuals diagnosed with 
concomitant heart disease and COPD are two to five times more likely to die of heart 
disease or stroke compared to those with heart disease alone.29,30 These two chronic 
diseases are also associated with a number of other worse patient outcomes. 
Prior investigators found that patients with comorbid COPD and HF reported 
decreased health-related quality of life, higher prevalence of anxiety and depressive 
symptoms, as well as the highest hospitalization rates among individuals with chronic 
diseases.33-35 Specifically, patients with heart failure reported 2.5 times poorer health 
related quality of life scores and 52% worse functional capacity scores, demonstrated 2.5 
to 3 times worse depression and anxiety scores compared to healthy individuals, and 
accounted for 25.6% of all hospitalizations.36,37 In patients with COPD, up to 99% of 
patients reported symptoms that impaired activities of daily living, and 7% to 80% 
reported feeling anxious and/or depressed.38,39 Patients with COPD were also 85% more 
likely to be diagnosed with an anxiety disorder, and twice as likely to be hospitalized for 
exacerbations when compared to healthy people. 13-16 In 2009, patients with COPD 
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accounted for approximately 16% of all hospitalizations.37 Other investigators found the 
combination of COPD and comorbid HF was associated with a 2.8 times greater 
likelihood of worse quality of life, and a dyspnea burden 2 to nearly 3 times greater than 
those with HF only.40,41 Thus, HF and COPD have a high symptom burden, poor 
outcomes and require significant healthcare utilization.  
Spirometry provides measures of inhaled and exhaled lung volumes, lung 
capacity, and rates of gas flow.4 Spirometry results provide information about the ability 
to ventilate, and can be used as a screening measure, diagnostic measure, or a means of 
disease monitoring.42 Diagnostic pulmonary function tests are more comprehensive and 
include measures of respiration like diffusion capacity, the degree to which oxygen is 
transferred from inhaled gas to erythrocytes in pulmonary circulation. Spirometry is used 
to evaluate pulmonary conditions but is not commonly used in patients with HF unless 
they have a suspected concomitant pulmonary condition. For this study, we used 
spirometry measures to evaluate pulmonary ventilation in patients with HF and suspected 
airflow limitation; these measures included forced vital capacity (FVC; liters), forced 
expiratory volume in one second (FEV1; liters at one second), and the ratio between the 
two (FEV1/FVC). 
FVC is the maximum volume of air that is forcibly exhaled after a full inspiration; 
the residual volume remains in the lungs and when added to the FVC provides the total 
lung capacity. FVC is measured in liters and like FEV1, is compared to a predicted value 
based on sex, age, height and weight.4,43 FEV1 is the volume of air forcefully exhaled in 
one second after a full inspiration; it provides an evaluation of airflow. When the FEV1 is 
less than 80% of the predicted value, airflow limitation is present.4,43 The ratio of FEV1 to 
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FVC, also known as the Tiffeneau-Pinelli index, is the proportion of vital capacity that an 
individual can forcefully exhale in the first second, and may be used to differentiate 
obstructive from restrictive disease and identify disease severity.4,43 An FEV1/FVC < 
0.70 is the global standard cut point for airflow obstruction/COPD.4 In those individuals 
with FEV1/FVC < .70 after bronchodilator administration, individuals are then classified 
based on severity of airflow limitation (Table 1.). 
Spirometry measures that revealed airflow limitation were associated with poorer 
outcomes that included worse quality of life, more hospitalizations, and mortality in 
patients with COPD.44-46 Spirometry indices predicted mortality in patients with COPD, 
and those with reduced FEV1 and FVC, had 43% to 50% higher associated risks for 
mortality compared to those with normal values.47 Despite the overlap in signs, 
symptoms, and pathological presentations, spirometry is not regularly performed in 
patients with HF; thus, the relationship between spirometry measures and combined 
hospitalization/mortality in patients with HF and airflow limitation has not been 
systematically studied.46,48,49 Therefore, the purpose of this study was to explore the 
predictive power of spirometry measures on event-free survival in patients with HF and 
suspected airflow limitation. The specific aims were to: 1) determine the proportion of 
patients with HF who exhibited airflow limitation (FEV1 < 80%) and met the spirometry 
criteria for COPD (FEV1/FVC < 70%); and 2) determine the independent predictive 
power of FEV1, FVC, and FEV1/FVC on a combined endpoint of 
hospitalization/mortality, while controlling for age, gender, ethnicity, smoking history, 
body mass index, left ventricular ejection fraction, and New York Heart Association 
(NYHA) functional class. 
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Methods 
Design and Sample 
This was a secondary analysis of data from a registry of three prospective, 
longitudinal studies conducted between 2008-2011.50-52  Each of the study protocols were 
reviewed and approved by respective Institutional Review Boards. These studies 
conformed to the principles outlined in the Declaration of Helsinki. Informed, written 
consent was obtained from all participants after they were approached by a trained 
research nurse who confirmed patient eligibility, explained the study requirements, and 
all risks. Individuals were included if they had a primary diagnosis of HF, read/spoke 
English, had no obvious signs of cognitive impairment, and were at least 18 years old.50-
52 Patients were recruited from a southern academic medical center in the United States.  
For this analysis, we filtered the original data registry to obtain only those cases with 
complete data for specific sociodemographic and clinical variables that might confound 
our analyses, and for our variables of interest, spirometry measures (FVC, FEV1, 
FEV1/FVC) and the outcome, time to combined hospitalization/mortality. There were 137 
participants with complete data included in this secondary analysis.  
Measures 
Demographic and Clinical Variables 
Sociodemographic and clinical data were collected by patient interview and 
review of medical records. Demographic variables included age, gender, and ethnicity. 
Clinical variables included smoking status, left ventricular ejection fraction (LVEF), New 
York Heart Association (NYHA) functional class, and body mass index (BMI). 
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Spirometry 
Spirometry measures were obtained from enrolled patients to determine the 
prevalence and degree of occult airflow limitation. All spirometry measures were made 
by fully trained respiratory therapists according to the American Thoracic Society’s 
guidelines for acceptability and reproducibility of lung function testing.43,53 GOLD 
criteria4 were used to establish cut points for airflow limitation and COPD. Per GOLD 
criteria, airflow limitation was defined as [actual FEV1/predicted FEV1 ] < 80%; this was 
the cut point used to identify participants with airflow limitation for this analysis.4 
Airflow obstruction (COPD) was defined as a FEV1/FVC < 70%; this is the cut point 
used to identify patients with probable COPD for this analysis.4  
Combined Hospitalization/Mortality  
The outcome of interest in this study was time to the composite end-point of all-
cause combined hospitalization/mortality. Patients in this study were followed for up to 
four years (maximum = 1454 days), and data about all hospitalizations and mortality 
were collected. Every patient previously identified family member or specified friend was 
contacted with monthly phone calls to evaluate health status. Events reported were 
confirmed by review of medical records or death certificate. All events were confirmed 
and classified by a trained cardiac nurse and heart failure expert.    
Data Analysis  
Patient characteristics were summarized using means, standard deviations or 
frequencies. Participants were grouped based on the FEV1 % of predicted with 0.80 used 
as the cut point, and were divided into those with airflow limitation or no airflow 
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limitation.4  These groups were compared with an independent t-test, Chi-square, or 
Fisher’s exact analysis based upon level of measurement and distribution of data. To 
respond to Specific Aim 1, patients were grouped based on FEV1 value; individuals with 
an FEV1 of < 80% of predicted were considered to have airflow limitation; those with an 
FEV1 < 70% of predicted were categorized as COPD.   
To address Specific Aim 2, we performed Cox proportional hazard modeling. The 
relationship between spirometry values and the composite outcome of combined all-cause 
hospitalization/mortality was tested with and without adjusting for age, gender, ethnicity, 
smoking status, LVEF, and BMI. First, spirometry data (FEV1, FVC and FEV1/FVC) 
were analyzed as continuous variables independently and with the control variables, 
using Cox proportional hazards regression to examine the overall effect of spirometry on 
combined all-cause hospitalization/mortality. Then, Cox proportional hazards regression 
modeling was conducted using participant classification of those with airflow limitation 
(FEV1 < 80%) and/or presence of COPD (FEV1/FVC < .70), with and without control 
variables. All test assumptions were evaluated prior to analysis. All data analyses were 
performed using SPSS version 24.0 (IBM, Armonk, NY), and a p value of < 0.05 was 
considered significant. 
Results 
Characteristics of the participants 
Participants in this study were primarily male (68%), Caucasians (79%) who were 
60 + 12 years of age (Table 2.). Slightly more than half of participants were in NYHA 
functional class I or II (52%), and on average the LVEF was 36 + 15%. Approximately 
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42% of participants reported never smoking, while 18% reported they were current 
smokers. Baseline spirometry measures averaged FVC of 2.98 + 0.90 L (74% of 
predicted value), an FEV1 of 2.24 + 0.68 L/sec (69% predicted value), and FEV1/FVC of 
0.75 + 0.08. Only 10% of participants had received a prior diagnosis of COPD. The 
follow up period for the composite outcome of hospitalization/mortality ranged from 7 
days to 1454 days. There were 199 hospitalizations during this period and 9 participants 
died. Mean time to first event was 378 + 270 days.   
Prevalence of airflow limitation 
  We first categorized patients based on FEV1 and FEV1/FVC (Table 3). Overall, 
74% (n = 102) of participants exhibited some degree of airflow limitation (FEV1 < 80% 
predicted value) and 26 (19%) participants met the spirometry criterion for COPD 
(FEV1/FVC < 0.70). Only 14 participants were previously diagnosed with COPD; thus, 
9% of total participants met spirometry criterion for COPD, but had not been diagnosed.  
Association of spirometry measures as continuous variables with event-free survival 
Cox proportional hazard regression demonstrated no significant effect of FVC, 
FEV1, or FEV1/FVC on event free survival when treated as continuous variables, with 
and without controlling for potential confounding demographic and clinical variables 
(Table 4.) The overall Cox proportional hazard regression was insignificant; there was no 
significant effect of spirometry measures independently or after controlling for potential 
confounding variables on all-cause hospitalization/mortality. However, FEV1 was 
significantly correlated with time (days) until first event (r = .22, p = .01), which 
indicated that as FEV1 decreased (greater airflow limitation), time to event was shorter.  
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Association of spirometry groups and event-free survival 
In simple Cox regression modeling (Table 5.), airflow limitation (FEV1 < 80%) 
independently predicted all-cause event-free survival (HR: 2.40, 95% CI 1.22 – 4.69, p = 
.01). After controlling for age, gender, ethnicity, smoking status, LVEF, and BMI, 
patients who demonstrated airflow limitation had 2.2 times the risk of 
hospitalization/mortality (HR: 2.20, 95% CI 1.06 – 4.53, p = .03) when compared to 
patients with no airflow limitation (Figure 1). Those in NYHA class III/IV were 73% 
more likely to have an event (HR: 1.73, 95% CI 1.00 – 3.01, p = .05) when compared 
with those in NYHA class I/II; conversely, if patients reported they had never smoked, 
they were 62% (HR: 0.38; 95% CI 0.17 - 0.81, p = .01) less likely to have a health-related 
hospitalization/death when compared to patients who currently had or ever had a smoking 
habit.  
Discussion  
We found that a majority of participants with HF (73%) had some degree of 
airflow limitation, and approximately 19% of participants met diagnostic criteria for 
COPD based on spirometry; 9% (n = 12) of these patients were unaware their spirometry 
measures were consistent with a diagnosis of COPD. Moreover, a FEV1 < 80% was 
highly associated with our combined composite endpoint of hospitalization/mortality; 
NYHA functional class III/IV was also associated with increased risk for 
hospitalization/mortality. Never smoking was associated with a reduced risk for an event. 
There was no association between FVC, FEV1/FVC (as continuous or categorical), age, 
gender, ethnicity, LVEF, or BMI with event-free survival in this sample of patients with 
HF.  
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Other investigators have explored the prevalence of airflow limitation and COPD 
in patients with HF; in prior research studies, 49% - 81% of patients with HF 
demonstrated airflow limitation and 11% - 39% of patients met spirometry criterion for 
COPD.46,48,49,54,55 In our sample of patients with HF, we found that the prevalence of 
airflow limitation (74%) and COPD (19%) was similar. However, there was considerable 
variability in the characteristics of the participants in prior studies, the procedures and 
equipment used, and criteria used to identify airflow limitation. For example, Arnaudis 
and colleagues48 studied patients with more advanced HF (higher proportion of patients 
in NYHA III/IV) who were clinically unstable; while Bektas and colleagues54 studied 
patients with less advanced disease (higher proportion of NYHA class I/II) who were 
clinically stable. Bektas and colleagues54 also measured patient spirometry after 
administration of a bronchodilator; while Plesner and colleagues46 measured spirometry 
without bronchodilator. Wada and colleagues55 used a handheld spirometer and 
diagnostic criteria based on FEV1/FEV6 to identify airflow limitation, rather than 
conventional office-based measures and GOLD criteria.4 Plesner and colleagues 46 used 
standardized, calibrated spirometry equipment and the European Respiratory Society’s 
standards and guidelines; other investigators did not clearly describe the procedure and 
equipment used.49 Thus, there is a clear need for investigators to use standardized, 
calibrated equipment and procedures for spirometry measures, and criteria for airflow 
limitation, so that reported results between studies will be comparable. 
Few prior investigators explored the association of spirometry measures with all-
cause hospitalization or mortality in patients with HF.46,48,49 We analyzed the overall 
effect of airflow limitation, rather than diagnosis of COPD in our analyses and found that 
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patients with any degree of airflow limitation had more than twice the risk of 
hospitalization/death. Similarly, Plesner and colleagues46 found that FEV1  was 
independently associated (HR 1.43, 95% CI 1.21 – 1.68, p < .001) with all-cause 
mortality after adjusting for similar potential confounding variables; however, Arnaudis 
and colleagues48 reported FEV1 was significantly associated with all-cause mortality only 
in the presence of verified COPD (GOLD stage II: HR: 2.28, 95% CI 1.218–4.25; p = 
0.01; GOLD stage III/IV: HR: 2.81, 95% CI 1.03–7.69; p = 0.044). Other investigators 
developed inconsistent conclusions about COPD (FEV1/FVC < 0.70) as a significant 
prognostic indicator of event-free survival. Plesner and colleagues46 concluded that a 
COPD diagnosis was not significantly associated with all-cause mortality after 
controlling for demographic and clinical variables (HR: 1.26, 95% CI: 1.85-1.87, p = 
.26);46 similarly, Mascarenhas and colleagues49 also concluded that a diagnosis of COPD 
was not significantly associated with all-cause mortality after controlling for potential 
confounding variables (HR: 1.40, 95% CI 0.88-2.24).49 Thus, our findings are consistent 
with previous investigators and demonstrate that airflow limitation rather than COPD 
diagnosis was associated with increased risk for all-cause hospitalization/mortality.  
Overall, our participant characteristics were similar to those in previous 
studies.46,48,49 However, our results must be weighed cautiously when compared to the 
results of other studies. Our sample averaged a 12% lower proportion of patients in 
NYHA class I/II than in our analyses; our participants were 4 years younger on average, 
we had 6% fewer males on average, and had a 6% greater average LVEF compared to 
those in other investigations.46,48,49  We also studied a different endpoint from other 
investigators. We combined time to first hospitalization and mortality, rather than solely 
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hospitalization or mortality.46,48,49 We studied this endpoint to determine the association 
between airflow limitation and time to both events in this population. Thus, our findings 
demonstrated a significant association between airflow limitation and 
hospitalization/mortality in our patients with HF. This finding could aid in the 
identification of patients likely to require hospitalization and may permit optimization of 
both cardiac and pulmonary function and improvement in outcomes.    
We also found that NYHA class III/IV and never smoking were significantly 
associated with all-cause hospitalization/mortality. We found that worse functional class 
was associated with 73% greater likelihood of an event (HR: 1.73, 95% CI 1.00 - 3.01, p 
= .05). Several other investigators found that worse functional class was associated with 2 
to 2.25 times greater likelihood of all-cause mortality.46,48,49 Our results are consistent 
with previous investigators; thus, as functional class worsened, there was a consistently 
increased risk for all-cause hospitalization/mortality. We also found that never smoking 
was protective for our endpoint, all-cause hospitalization/mortality. Our participants who 
had never smoked reduced their risk of hospitalization/mortality by 62% compared to 
those who were current smokers or had previously smoked (HR: 0.38, 95% CI, 0.17 – 
0.81, p < .01). Plesner and colleagues also found that current smokers had a 64% greater 
risk of  mortality compared to non-smokers (HR: 1.64, 95% CI 1.10 – 2.43, p = .014).46  
Limitations  
 This study was a secondary data analysis; thus, we could include only the 
variables measured in the primary studies. We also had no ability to appraise data for 
accuracy or evaluate fidelity to study protocols. However, spirometry measures were 
made in a pulmonary function laboratory using standardized equipment, procedures and 
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highly trained personnel. Our spirometry data were measured without the use of 
bronchodilation. Thus, our estimates of the prevalence may have included those with 
some degree of reversible airflow limitation. All data were evaluated for accuracy by the 
original investigative team and all data were double entered and evaluated for entry 
accuracy prior to analysis.  
Conclusions 
A majority of our participants demonstrated some degree of airflow limitation. 
Airflow limitation more than doubled the risk of all-cause hospitalization/mortality in our 
patients with HF. Worse NYHA functional status was also associated with shorter 
survival time; never smoking reduced the likelihood of hospitalization/mortality. 
Spirometry measures may be useful in patients with HF, as tailored management of 
airflow limitation may improve all-cause survival.  
Implications for practice 
• Airflow limitation was common (74%) in this group of individuals with HF. 
• Airflow limitation increased risk of hospitalization/death by 220%. 
• Worse NYHA functional class was associated with 73% increased risk of shorter 
survival time.  
• Non-smokers were 62% less likely to be hospitalized/die compared to smokers. 
• Patients with HF may be unaware they have airflow limitation or occult COPD; 
approximately 10% of patients did not have a previous diagnosis of COPD but 
met spirometry criteria for COPD.  
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Table 2.1. Classification of airflow limitation severity based on FEV1 in patients with 
FEV1/FVC < 0.70 
GOLD Stage Severity FEV1 
GOLD Stage 1 Mild FEV1 > 80% predicted 
GOLD Stage 2 Moderate 50% ≤ FEV1 ≤ 80% 
predicted 
GOLD Stage 3 Severe 30% ≤ FEV1 ≤ 50% 
predicted 
GOLD Stage 4 Very Severe  FEV1 < 30% predicted 
Abbreviations: GOLD, Global Initiative for Obstructive Lung Disease; FEV1, Forced 
Expiratory Volume in one second 
Source: From the Global Strategy for the Diagnosis, Management and Prevention of 
COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017. 
Available from: http://goldcopd.org/. 
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Table 2.2. Participant characteristics 
 Total sample  
N = 137 
 
Airflow Limitation 
[FEV1 < 80% 
predicted]  
n = 102 (74%) 
 
No Airflow 
Limitation 
[FEV1 ≥ 80% 
predicted]  
n = 35 (26%) 
P 
value 
Age in years 60 + 12 59 + 11 63 + 13 .28 
Gender 
   Male 
 
93 (68%) 
 
70 (69%) 
 
23 (66%) 
 
.75 
Ethnicity 
   Caucasian 
   Other 
 
108 (79%) 
29 (21%) 
 
75 (74%) 
27 (26%) 
 
33 (94%) 
2 (6%) 
 
.01 
Smoking History 
   Current smoker 
   Stopped smoking 
   Never smoked 
 
24 (18%) 
56 (41%) 
57 (42%) 
 
21 (21%) 
41 (40%) 
40 (39%) 
 
3 (9%) 
15 (43%) 
17 (49%) 
 
.25 
BMI 32.7 + 7.7  33.4 + 7.7 30.7 + 7.2 .13 
LVEF % 36 + 15 35 + 15 39 + 14 .15 
Prior Diagnosis of 
COPD? 
 
14 (10%) 
 
14 (13%) 
 
1 (3%) 
 
.12 
Spirometry: 
FEV1/FVC < 0.70 
26 (19%) 26 (26%) 0 (0) - 
NYHA Functional 
Class 
   I/II 
   III/IV 
 
 
71 (52%) 
66 (48%) 
 
 
49 (48%) 
53 (52%) 
 
 
22 (63%) 
13 (37%) 
 
 
.13 
Values are mean + SD or f (%) 
Comparisons were performed with independent t tests, Chi square or Fisher’s exact test 
based on level of measurement and distribution of data.  
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Table 2.2, Cont. 
Abbreviations: FEV1, forced expiratory volume in one second; FVC, forced vital 
capacity; NYHA, New York Heart Association Functional Class; LVEF, left 
ventricular ejection fraction; BMI, body mass index 
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Table 2.3. Baseline spirometry for participants 
 
 
 
 
 
 
 
 
 
 
 
Spirometry Measure Total sample  
(n = 137) 
Airflow 
Limitation 
(FEV1 < 80% 
predicted value) 
(n = 102) 
 Normal Airflow  
(FEV1 ≥ 80% 
predicted value) 
(n = 35)  
FVC measured in liters 
Predicted FVC for the total sample 
Percent predicted  
2.98 + .90 
4.03 + .95 
74.8 + 18 
2.81 + 0.87 
 
3.34 + 0.87 
 
FEV1 measured in liters 
Predicted FEV1 for the total 
sample 
Percent Predicted  
2.24 + .68 
3.23 + .78 
 
70.2 + 18 
2.06 + 0.64 
 
2.66 + 0.65 
 
FEV1/FVC (%) 
Predicted FEV1/FVC for total 
sample 
75.27 + 8.65 
80.64 + 2.20 
73.64 + 9.05 80.03 + 5.01 
Values are mean + SD or f (%) 
Abbreviations: FEV1, forced expiratory volume in one second; FVC, forced vital capacity 
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Table 2.4. Cox Regression Modeling: Spirometry Measures as Continuous Variables 
with and without Covariates on Combined All-Cause Hospitalization/Mortality   
 Variables in Model Exp (β) 95% CI p value 
Bl
oc
k 
1 
a     FVC .71 .19 – 2.56 .60 
   FEV1  1.35 .22 – 8.32 .75 
   FEV1/FVC  .98 .92 – 1.04 .46 
Bl
oc
k 
2b
 
   Age  1.03 .99 - 1.05 .08 
   Male .67 .34 - 1.36 .19 
   Caucasian .64 .31 – 1.33 .23 
   Never smoked .36 .16 – .79 .01 
   NYHA Class III/IV 1.85 1.06 - 3.22 .03 
   LVEF 1.01 .99 - 1.03 .33 
   BMI 1.02 .98 - 1.06 .20 
  FVC .80 .19 – 3.30 .76 
  FEV1  1.49 .20 – 11.00 .69 
  FEV1/FVC  .98 .92 – 1.04 .49 
Abbreviations: FEV1, forced expiratory volume in one second; FVC, forced vital 
capacity; NYHA, New York Heart Association Functional Class; LVEF, left 
ventricular ejection fraction; BMI, body mass index;  
Omnibus Tests of Model Coefficients: a X2 = 2.31, p = .51; b X2 = 18.83, p = .09 
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Table 2.5. Cox Regression Modeling: Spirometry Measures using GOLD Cut points 
with and without Covariates on Combined All-Cause Hospitalization/Mortality   
 Variables in Model Exp (β) 95% CI p value 
Bl
oc
k 
1 
a 
   FEV1 < 80%  2.40 1.22 – 4.69 .01 
   FEV1/FVC < 0.70 .93 .50 – 1.74 .82 
Bl
oc
k 
2b
 
   Age  1.02 .99 - 1.05 .07 
   Male .74 .34 - 1.24 .19 
   Caucasian .76 .36 – 1.61 .48 
   Never smoked .38 .17 – .81 .01 
   NYHA Class III/IV 1.73 1.00 - 3.01 .05 
   LVEF 1.01 .99 - 1.03 .17 
   BMI 1.02 .98 - 1.05 .37 
FEV1 < 80% 2.20 1.06 – 4.53 .03 
FEV1/FVC < 0.70 .90 .44 – 1.83 .77 
Abbreviations: FEV1, forced expiratory volume in one second; FVC, forced vital 
capacity; NYHA, New York Heart Association Functional Class; LVEF, left 
ventricular ejection fraction; BMI, body mass index;  
Omnibus Tests of Model Coefficients: a X2 = 7.83, p = .03; b X2 = 22.03, p = .02 
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Figure 2.1. Kaplan-Meier plots: spirometry and all-cause event-free survival (X2 = 
22.03, p = .02) 
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CHAPTER THREE 
The Multidimensional Scale of Perceived Social Support in patients with Comorbid 
COPD and Heart Failure: A psychometric analysis.  
 
Synopsis 
Chronic disease self-management is complex and multidimensional; individual 
ability to perform self-management behaviors is influenced by comorbid conditions, 
somatic awareness, and perceived social support. Optimal performance of complex self-
management behaviors requires individuals have the support of their friends, family 
members, and significant others. This secondary data analysis reported the psychometric 
properties of the Multidimensional Scale of Perceived Social Support (MSPSS) in 
patients with comorbid chronic obstructive pulmonary disease (COPD) and heart failure 
(HF). The MSPSS demonstrated excellent internal consistency with Cronbach’s alpha 
consistently above .90. Factor analysis yielded a 3-factor solution, with items loading 
appropriately on the Friend, Family and Significant Other subscales. Hypothesis testing 
supported our hypothesis that higher levels of perceived social support predicted higher 
self-care management score. We concluded the MSPSS is a reliable and valid instrument 
to measure perceived social support in patients with comorbid COPD and HF.  
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Introduction 
Chronic and obstructive pulmonary disease (COPD) and chronic heart failure 
(HF) are responsible for over 21 million deaths annually, and are two of the top four 
causes of global mortality.1,32 It is estimated that up to 52% of patients with HF have 
comorbid COPD.56  Comorbid COPD and HF are associated with a higher incidence of 
other cardiovascular diseases, such as atrial fibrillation/flutter and hypertension.57 
Moreover, the risk of developing HF among patients with COPD is 450% greater 
compared to healthy adults.58  COPD and HF are progressive and irreversible; patients 
are taught about daily self-care behaviors to maintain functional ability, reduce symptom 
burden, and maintain quality of life.13,19 Chronic disease self-care is complex and 
multidimensional; individual ability to perform self-care behaviors is influenced by 
comorbid conditions, somatic awareness, and perceived social support.13,59,60   
Optimal performance of complex self-care behaviors requires individuals to have 
the support of their friends, family members, and significant others. Perceived social 
support plays an important role in outcomes such as self-care ability, depression, and 
anxiety in patients with COPD. Previous investigators found that higher levels of 
perceived social support was associated with higher self-care abilities (r = 0.252; P = 
0.012), and was a significant predictor of reduced depression (β = -0.25, F(6, 85) = 5.10, 
p <.01) and anxiety (β = -0.20, F(6, 85) = 5.61, p <.01).59,61,62 Furthermore, lower levels 
of social support significantly predicted higher anxiety symptoms (F (11, 418) = 34.9, p < 
.001, R2 adj = .47). Increased loneliness was moderately associated with worsening 
depressive symptoms (r = −.587; p < .001) and reduced feelings of social support (r = 
29 
−.471; p < .01).63,64 Thus, perceived social support is an important factor in patient 
outcomes in those with COPD. 
In patients with HF, perceived social support has been shown to predict level of 
self-care ability (β = .33; p = .0002),65 and in a seminal study conducted by Riegel and 
Carlson,66 patients who underwent an intervention to improve peer and social support 
demonstrated a 8.7% increase in perceived self-care management ability (r = 0.46; 
moderate effect), and a 6% increase in self-care confidence (r = 0.62; moderate/large 
effect).66 In contrast, poorer social support was an independent predictor of reduced 
health-related quality of life (β = −.132; P < .001), worse depressive symptoms (sβ = 
−.467; P < .001) and was associated with a 50% increased risk of hospitalization and 
death.67,68 Thus, there is an apparent association between social support and key 
outcomes in patients with HF. 
It is unclear whether patients with comorbid chronic conditions like COPD and 
HF may require more perceived social support compared with individuals who have a 
single chronic condition. It is plausible that the additive self-care requirements from each 
disease would warrant greater perceived social support. It is vital that the instruments 
used to measure perceived social support have psychometric rigor in patients with 
comorbid conditions, so that the data obtained are reliable, valid and useful. Thus, the 
purpose of this secondary analysis was to examine the psychometric properties of the 
Multidimensional Scale of Perceived Social Support in patients with comorbid COPD 
and HF. The specific aims of this study were to provide evidence of internal consistency 
reliability and construct validity by factor structure and hypothesis testing. We 
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hypothesized that higher perceived social support scores would predict better self-care 
management.   
Methods 
Design and Sample 
This study was a secondary data analysis from a large, multicenter HF registry. 
This registry contains data from 4,076 inpatient and outpatient participants who were 
recruited from cardiology centers located in the Southern and Midwest United 
States.51,56,67-72 Recruitment and inclusion criteria were consistent across studies; study 
participants had a confirmed diagnosis of HF with either preserved or reduced ejection 
fraction, had a left ventricular ejection fraction (LVEF) < 40%, were 18 years or older, 
and had not had a myocardial infarction within three months of enrollment. The selected 
participants (N = 303) had complete data for demographic (gender, age, ethnicity, marital 
status, years of education, smoking history) and clinical variables (diagnosis of HF, 
diagnosis of COPD, LVEF, body mass index [BMI], New York Heart Association 
[NYHA] functional class), and scores on the Multidimensional Scale of Perceived Social 
Support (MSPSS), and self-management scores from the Self-Care for Heart Failure 
Index (SCHFI).  
Measures 
Demographic and clinical variables were collected by interview of patients and 
review of medical records. Demographic variables collected included gender, age, 
ethnicity, marital status, years of education and smoking history. Clinical variables 
include current diagnosis of COPD and HF, LVEF, BMI and NYHA functional class. 
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Perceived Social Support  
There is no consensus definition of perceived social support. However, perceived 
social support is generally considered to be the physical, cognitive and psychological 
benefits of interacting with other people.73 Zimet and colleagues74 developed the 
Multidimensional Scale of Perceived Social Support (MSPSS) to measure perceived 
availability and sufficiency of support from family, friends and significant others.74 The 
MSPSS is a self-report instrument with 12 items that are rated on a 7-point Likert scale, 
ranging from 1 “strongly disagree” to 7, “strongly agree”; this instrument has 3 subscales; 
family, friends, and significant other. “Significant other” is intentionally undefined so 
that the respondent can identify their own significant other(s).74,75 The MSPSS is scored 
by summing the responses of the 12 items; total scores range from 12 to 84, and higher 
scores indicate higher levels of perceived social support. The three subscales are also 
scored individually and may be used independently in analyses.74,75  
Internal consistency for this instrument in patients with HF previously ranged 
from 0.85 to 0.94.68,76 During the initial instrument development, internal consistency for 
the subscales ranged from .85 to .91, and test-retest reliability ranged from .72 to .85;74,75 
internal consistency for the family, friends and significant other subscales in patients with 
HF were .94, .94, and .94 respectively.77 Adequate construct validity was demonstrated 
by repeated extraction of three factors in patients with HF77 as well as other populations 
including undergraduate students, pediatric residents, European adolescents, pregnant 
women and patients with end stage renal disease.74,75,77,78  
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Self-Care Management  
Self-care management is the process by which individuals with chronic disease 
attain optimal health through learned, intentional actions that include symptom 
recognition and response, adherence to prescribed treatment and medications, intentional 
lifestyle alterations, regular interaction with health care professionals, and evaluation of 
these actions.13 Self-care management was measured with the Self-Care Management 
subscale of the Self-Care of Heart Failure Index (SCHFI).79 The SCHFI comprises three 
subscales labeled self-care maintenance, self-care management, and self-care confidence; 
each scale is measured and evaluated independently.79 Only the self-care management 
subscale was used for our analyses because it assesses symptomatic patients and their 
ability to perform management level behaviors, which are theoretically indicative of self-
care mastery.80 This subscale contains six items that measure symptom recognition, 
implementation of treatment strategies, and evaluation of treatment strategies. This 
subscale uses a 4-point Likert scale where 1 signals rarely or never, 2 signals sometimes, 
3 indicates frequently, and 4 indicates always or daily. The six item scores are summed, 
then transformed to produce a standardized range of potential self-care management 
scores from 0 to 100; higher scores indicate better self-care management ability.79 A 
score of 70 or greater indicates adequate self-care management.79 Cronbach’s alpha for 
this subscale is acceptable and ranges from .597 to .70.79,80 Evidence of construct validity 
for the SCHFI and self-care management subscale is strong, with consistent extraction of 
three independent factors (for each of the three subscales) and consistent loading of the 
appropriate questions on the self-care management construct.79,80  
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Procedure 
The participants included in this secondary data analysis were recruited after each 
study was approved by the respective Institutional Review Board. All participants 
provided informed consent. Data were collected by nurse researchers who were trained to 
perform the study procedures. Nurse researchers were present during the data collection 
process to aid participants as needed. All data were double entered into a data spreadsheet 
(SPSS version 21, Armonk, NY) and evaluated for errors prior to analyses. We filtered 
the data registry to obtain those participants with complete data for the demographic, 
clinical and research variables of interest.      
Data Analysis 
Descriptive statistics, frequencies, means with standard deviations, and 
proportions were used to characterize the participants. To analyze the internal consistency 
of the MSPSS, Cronbach’s alpha was calculated for the total instrument and three 
subscales. Item-item correlations were analyzed to ensure all correlation coefficients 
were above 0.3 and below 0.9. Split-half reliability analyses were also conducted for the 
total scale. A principal components factor analysis with a direct oblimin rotation was 
conducted to examine the factor structure of the 12-item MSPSS. Sampling adequacy 
was confirmed by a Kaiser-Meyer-Olkin measure above 0.5.81 Bartlett’s test of sphericity 
was conducted to assess if correlations between items were sufficiently large to conduct 
the analysis; a significant level of < .05 was used as the cut point for this analysis.81 To 
further examine the construct validity of the MSPSS, hypothesis testing was performed 
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using multiple linear regression. We hypothesized that higher perceived social support 
score was a predictor of better self-care management score after controlling for age, 
gender, ethnicity, marital status, living situation, smoking status, education level, BMI, 
LVEF, and NYHA class. All data analyses were conducted using SPSS Version 24.0 
(IBM, Armonk, NY). An a priori α level of < 0.05 was used to determine significance.  
Results 
Characteristics of the participants 
Participants with comorbid COPD and HF (N = 303) were primarily male (63%), 
Caucasians (65%) aged 61 + 12 years on average (Table 1.) A majority of these 
participants were married or cohabiting (60%) and 74% reported living with someone. 
Approximately two thirds (62%) of participants were classified as NYHA class III/IV 
with an average LVEF of 37 + 15%. A majority of participants had a prior smoking habit 
but had quit (43%), and 19% were current smokers. The average participant had 12.4 + 
3.6 years of education. Total perceived social support scores were moderately high with 
an average score of 63.5 + 17.3 Average self-care management scores (55 + 20) were 
below the recommended cutoff of 70, indicating poor self-management scores in these 
participants.  
Internal Consistency Reliability 
The MSPSS demonstrated excellent internal consistency yielding a Cronbach α = 
0.93 for the total instrument, 0.95 for the Friend subscale, 0.92 for the Family subscale, 
and 0.92 for the Significant Other subscale. Analysis of item-item correlations ranged 
from .347 - .884. Cronbach’s α did not increase during removal of each item during 
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reliability assessment. Split-half reliability analyses of the MSPSS resulted in a 
Spearman-Brown coefficient of .92; a Spearman-Brown coefficient above .80 indicates 
adequate correlation between split halves, and a good indicator of internal consistency of 
the MSPSS in this sample.81  
Construct Validity 
A principal components analysis was conducted on the 12 items of the MSPSS 
with a direct-oblimin rotation for this sample of patients with comorbid COPD and HF 
(Table 2.). A preliminary analysis was conducted to ensure the data were appropriate for 
further analysis by evaluation of the Kaiser-Meyer-Olkin statistic and Bartlett’s test of 
sphericity. The Kaiser-Meyer-Olkin measure ensured sampling adequacy for this analysis 
with a KMO = .880, which is well above the recommended cutoff of  ≥ 0.60.81 Bartlett’s 
test of sphericity (X2 (66) = 3393.17, p < .001) indicated that the correlations between 
items were sufficiently large to conduct the analysis.81 An initial analysis was conducted 
to obtain eigenvalues for each factor. Three factors had eigenvalues greater than Kaiser’s 
criterion of 1 and accounted for 82.4% of the total variance; factor one had an eigenvalue 
of 6.89, accounting for 57.4% of the total variance, and the other two factors combined 
for 14.7% (eigenvalue 1.77) and 10.2% (eigenvalue 1.23) of the total variance.82,83 The 
scree plot clearly supported a three-factor solution evidenced by a modest drop off after 
the third factor. Thus, three factors were retained for the final analysis. A factor cut-off 
was set at 0.40, with loadings below .40 eliminated from the final model.84 As a result, 
there were no cross loadings of items between the three factors. Items that clustered on 
the same factor suggested that component 1 represented the Family subscale, component 
2 represented the Friends subscale and component 3 the Significant Other subscale. The 
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extraction of three factors with no cross loadings replicated the original instrument 
development and provided support for the three-factor structure in those with comorbid 
COPD and HF.74,75  
Multiple linear regression was used to evaluate construct validity of the MSPSS 
(Table 3.). We hypothesized that higher perceived social support score would be an 
independent predictor of better self-care management score after controlling for age, 
ethnicity, marital status, living alone, education level, smoking history, BMI and NYHA 
functional class. All variables were entered into the regression model in one block. The 
assumptions of linearity, independence of errors, homoscedasticity, outliers, and 
normality of residuals were evaluated and met before interpretation of results. In this 
model, perceived social support score significantly predicted self-care management score 
(F[11, 291] = 2.463, p < .01, R2 = .085, adj R2 = .051). Specifically, higher LVEF (B = -
.234, p < .01) and better perceived social support score (B = .151, p = 0.03) were 
significant predictors of self-care management scores. Higher perceived social support 
was predictive of higher self-care management score; for every 1 unit increase in the 
MSPSS score, there was an associated 0.151 unit increase in self-care management score. 
For every 1% increase in LVEF, there was a 0.234 decrease in self-care management 
score. No other covariates were significant predictors of self-care management.  
Discussion 
We provided evidence that the MSPSS is a valid and reliable instrument when 
used to measure perceived social support in patients with comorbid COPD and HF. Our 
results supported the MSPSS as a highly reliable instrument with Cronbach’s α 
consistently above .90 in these participants. Results from our factor analysis using 
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principal components yielded a 3-factor structure consistent with the factor structure 
elicited during the original scale development and with previous investigators.74,75,77 We 
also conducted hypothesis testing to further test the construct validity of the MSPSS. We 
found that perceived social support score and LVEF significantly predicted self-care 
management score, which further supported the construct validity of the MSPSS in this 
population.  
Our results demonstrated excellent internal consistency. However, Cronbach’s α 
surpassed the recommended threshold of .90, indicating potential redundancy within the 
scale. Several items examined in the item-item correlation matrix had coefficients near 
.90; the correlation coefficient between item 6 (My friends really try to help me) and 7 (I 
can count on my friends when things go wrong) was .868; the correlation coefficient 
between item 9 (I have friends with whom I can share my joys and sorrows) and 12 (I can 
talk about my problems with my friends) was .884. High item-item correlations suggested 
redundant examination of perceived social support from friends. To further test for 
redundancy, the examination of Cronbach’s α with deletion of items from the scale was 
conducted; Cronbach’s α did not decrease below .90 when items were deleted, indicating 
redundancy was unlikely. Thus, our findings support strong reliability of the MSPSS in 
patients with COPD and HF.   
A factor analysis using principal components with a direct oblimin (oblique) 
rotation yielded a 3-factor structure with items loading on each of the friend, family and 
significant other subscales. These results are consistent with previous factorial validity 
testing of the MSPSS; in patients with HF,77 pregnant women,75 adolescents,75,78 and  
undergraduate students.74 A three-factor structure was produced with items corresponding 
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to the dimensions of friends, family and significant other. The findings of our analysis are 
consistent with previous investigator’s findings and support a three-dimension solution in 
patients with concomitant COPD and HF.  
Previous investigators have supported the importance of perceived social support 
in performing self-care in COPD and HF populations separately; however, to our 
knowledge, investigators have not tested the association of perceived social support with 
self-care scores in patients with comorbid COPD and HF. Our results confirmed findings 
from previous investigators who found that higher levels of perceived social support were 
associated with better self-care management score.59,62,65,66 Thus, social support is an 
important factor to consider when measuring self-care management for those with 
comorbid conditions such as COPD and HF. 
Additionally, we also observed that LVEF was a predictor of self-care 
management score. For every 1% increase in LVEF, there was a 0.234 decrease in self-
care management score. This finding is consistent with previous investigators who 
studied self-care management in patients with HF alone. Lee and colleagues 85 found that 
worse functional class (NYHA III/IV) and higher ejection fraction were significant 
predictors of poorer consulting behaviors; consulting behaviors were defined as actions 
taken by patients to seek guidance about worsening symptoms.85 Patients with poor 
consulting behaviors scored an average 12.3 points lower on the self-care management 
subscale of the SCHFI compared to those patients who had good consulting behaviors.85 
Patients who did not have highly burdensome symptoms or greater functional impairment 
may have not needed to engage in self-care management behaviors;85,86 the self-care 
management subscale is most relevant to symptomatic patients.80 Thus, patients with a 
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higher LVEF likely had a lower symptom burden, which required less self-care 
management; subsequently, these patients may not have fully developed self-care skills.  
Limitations 
 The participants included in this secondary data analysis were derived from a 
registry of patients with HF; thus, we had no control over the variables measured or the 
data collection process and could not appraise the data for accuracy or validity. The 
MSPSS and the SCHFI are self-report instruments and may be subject to social 
desirability bias. However, all data collection procedures were designed to reduce the 
potential for bias, and data input was evaluated by the original investigators for accuracy 
prior to analysis.  
Conclusion 
 The MSPSS was demonstrated to be a reliable and valid measure of perceived 
social support from friends, family and significant others in patients with COPD and HF. 
Further studies are warranted to determine the psychometric properties of the MSPSS in 
patients with solely COPD, as well as to examine the relationship between comorbidities, 
perceived social support and self-care.  
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Table 3.1. Sample Characteristics (N = 303) 
Variable f (%) or mean + SD 
Age in years 61 + 12 
Gender 
   Male 
 
192 (63) 
Ethnicity 
   Other 
   Caucasian 
 
105 (35) 
198 (65) 
Marital Status 
   Single/Widowed 
   Married/cohabitate 
   Divorced/Separated 
 
64 (20) 
181 (60) 
58 (19) 
Live with someone 
   Yes 
 
225 (74) 
Education in years 12.4 + 3.6 
Smoking History 
   Current smoker 
   Non-smoker 
 
25 (34.7) 
47 (65.3) 
BMI 31.5 + 7.9 
LVEF 37 + 15 
NYHA class 
   I/II 
   III/IV 
 
116 (38) 
187 (62) 
Perceived Social Support (MSPSS) 
   Total score 
   Friend subscale 
   Family subscale 
   Significant Other subscale 
 
64 + 17 
19 + 8 
22 + 7 
23 + 7 
Self-care management 
(SCHFI subscale) 
55 + 20 
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Table 3.1, Cont. 
Abbreviations: BMI, body mass index [kg/m2], LVEF, left 
ventricular ejection fraction, NYHA, New York Heart 
Association functional class 
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Table 3.2. Rotated Pattern Matrix of the Multidimensional Scale of Perceived Social 
Support in patients with COPD and HF (N = 303) 
Item Rotated Factor Loadings 
Factor 
1 2 3 
Fr
ie
nd
 S
up
po
rt
 
6. My friends really try to help me. .037 -.895 -.013 
7. I can count on my friends when things go 
wrong. 
.014 -.936 .016 
9. I have friends with whom I can share my 
joys and sorrows. 
-.012 -.914 -.035 
12. I can talk about my problems with my 
friends. 
.024 -.931 .003 
Fa
m
ily
 S
up
po
rt
 
3. My family really tries to help me. .929 -.019 .070 
4. I get the emotional help and support I 
need from my family. 
.895 -.004 -.052 
8. I can talk about my problems with my 
family. 
.773 -.086 -.081 
11. My family is willing to help me make 
decisions. 
.903 .027 -.004 
Si
gn
ifi
ca
nt
 O
th
er
 S
up
po
rt
 1. There is a special person who is around 
when I am in need. 
.116 .140 -.867 
2. There is a special person with whom I can 
share my joys and sorrows. 
-.100 -.088 -.913 
5. I have a special person who is a real 
source of comfort to me. 
-.030 -.116 -.877 
10. There is a special person in my life who 
cares about my feelings. 
.071 .002 -.834 
Initial Eigenvalues 6.890 1.767 1.227 
Rotated Eigenvalues (direct oblimin) 5.143 5.115 5.274 
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Table 3.3. Multiple Linear Regression Variables Predicting Self-Care Management 
Score (N = 303) 
 
Model 
Variable 
Unstandardized 
Coefficient 
Standard 
error of the 
coefficient 
Standardized 
coefficient 
P value 
Age .112 .107 .065 .30 
Gender 3.546 2.711 .084 .19 
Ethnicity .010 2.416 .000 .99 
Marital Status .937 1.394 .043 .50 
Living 
Situation 
-.189 2.825 -.004 .95 
Education 
Level 
.141 .350 .025 .69 
Smoking 
History 
1.778 1.163 .096 .13 
BMI .153 .163 .059 .35 
LVEF -.319 .084 -.234 < .01 
NYHA Class 1.175 1.644 .044 .48 
Perceived 
Social 
Support 
(MSPSS total 
score) 
.151 .070 .128 .03 
Abbreviations: NYHA, New York Heart Association Functional Class; LVEF, left 
ventricular ejection fraction; BMI, body mass index; MSPSS, Multidimensional 
Scale of Perceived Social Support 
R2 = .085, adjusted R2 = .051, df = 11, model F statistic = 2.463, p = .006 
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CHAPTER FOUR 
Effect of an eHealth Self-Care Educational Intervention on Symptom Severity and 
Variability, Psychological Distress, Self-Care Ability, and Treatment Adherence and 
Knowledge in Patients with COPD. 
Synopsis 
Patients with chronic obstructive pulmonary disease (COPD) experience a variety 
of burdensome symptoms and are at higher risk of developing psychological symptoms 
like anxiety and depressive symptoms compared with healthy individuals. Due to the 
high symptom burden and progressive nature of COPD, healthcare providers prepare 
patients with COPD to perform considerable self-care at home. This manuscript reported 
a study about the effect of a theory-based, self-care education program on symptom 
severity and variability, anxiety and depressive symptoms, perceived self-care ability, 
self-care adherence, and perceived knowledge needs in patients with COPD. This 
intervention resulted in significant change in symptom severity evaluation in subsets of 
patients. Perceived self-care ability was unchanged; however, perceived self-care 
adherence scores improved, and knowledge needs were significantly reduced after the 
intervention.    
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Introduction 
Chronic obstructive pulmonary disease (COPD) is predicted to be the third 
leading cause of death worldwide by 2030.1 In the United States, the estimated 
prevalence of COPD ranged from 15 to 22 million (7-9% of the U.S population).2,3 Up to 
99% of patients with COPD reported daily symptoms like dyspnea and fatigue, and 7% to 
80% of patients with COPD described feeling anxious and/or depressed. COPD patients 
are 85% more likely to be diagnosed with an anxiety disorder compared to healthy 
controls, and twice as likely to be hospitalized for acute exacerbations.23,38,87 Due to the 
high symptom burden and progressive nature of COPD, healthcare providers prepare 
patients with COPD to perform considerable self-care at home. However, Nici and 
colleagues24 suggested that approximately 60% of patients with COPD do not 
demonstrate prolonged retention of self-care behaviors.  
In the middle range theory of self-care of chronic illness, self-care is defined as 
the process by which individuals with chronic disease attain optimal health through 
learned, intentional actions that include symptom recognition and response, adherence to 
prescribed treatment and medications, intentional lifestyle alterations, regular interaction 
with health care professionals, and evaluation of these actions.16 The increased incidence 
and prevalence of COPD has been the impetus for the development of education and 
training programs focused on self-care behaviors for these patients. These structured, 
multi-faceted interventions aimed to educate, motivate, engage, and support patients to 
adapt their health behaviors and develop skills to prevent exacerbations requiring 
hospitalization, and to provide relief of symptoms. 4,14-17  
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There is a plethora of evidence to support an association between self-care 
interventions and decreased dyspnea burden in this population; patients receiving self-
care interventions exhibit a 4.1%, to 16.6% decrease in dyspnea post-intervention 
compared to controls.88-90  However, researchers have yet to demonstrate whether self-
care interventions have a significant effect on other highly burdensome symptoms such as 
distress due to cough, chest tightness, distress due to mucous production, or fatigue. 
Previous investigators have concluded that patients with COPD experienced an 
assortment of symptoms with varying levels of intensity and variability throughout the 
day, and from day to day; during any given day, 45.4% of people experience dyspnea, 
60.1% had troublesome cough, 70.9% reported distress from mucous, 45.4% had chest 
tightness, and 43.3% reported wheezing.5,91 Longitudinal symptom data in this population 
are lacking. Prior investigators predominately assessed symptom severity and variability 
using a cross-sectional approach, which failed to adequately capture daily symptom 
profiles over time.5,6,91 Consequently, researchers have been unable to examine the 
relationship between longitudinal trends in symptom variability and self-care strategies 
aimed to reduce symptom burden.  
Patients with COPD also experienced symptoms related to their mental health. 
Approximately 7-80% of patients with COPD described daily anxiety with up to 40% 
reporting symptoms consistent with clinical anxiety and 25% with clinically significant 
depressive symptoms.12,23,92 Previous investigators concluded that self-care interventions 
had no effect on anxiety and depression scores compared to those of a control 
group.88,89,93-95 However, poor or ineffective management of anxiety or depressive 
symptoms was independently associated with a 1.89 and 2.98 increased risk of 
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hospitalization, respectively.28 These investigators concluded that anxiety and depressive 
symptoms were important outcomes for patients with COPD, and future research is 
warranted to explore the relationships between self-care and mental health outcomes.  
To date, studies of self-care interventions have been primarily longitudinal with 
periodic measures of outcomes collected monthly over the course of 3 to 12 
months.88Studies of symptom severity and variability have primarily been cross-sectional 
and have not examined symptom patterns in patients with COPD. Prior investigators have 
not tested the effect of a self-care intervention on disease-related symptoms in the period 
immediately following an intervention. Thus, it is unclear how quickly improvement 
occurs after an intervention.    
Previous self-care interventions have improved health related quality of life  by 
4.87% – 6.5%,15,18 reduced dyspnea scores by an average 16.6%,88 decreased risk for all-
cause hospitalization by 40%,20,21,88 reduced anxiety by an average 2.7%, and reduced 
depression by an average of 2.9%.22,23 However, evidence is lacking  about the immediate 
effects of self-care interventions on perceived symptom severity and variability (distress 
due to cough, chest tightness, distress due to mucous, dyspnea, or fatigue), perceived self-
care ability, self-care adherence, and self-care knowledge. We also lack data about the 
use of electronic strategies for intervention delivery in this patient population. Thus, the 
purpose of this study was to test the effect of a theory-based, self-care education program 
using an eHealth platform on measures of symptom severity and variability (distress due 
to cough, chest tightness, distress due to mucous, dyspnea with activity, dyspnea at rest, 
fatigue, anxiety, and depressive symptoms), perceived self-care ability, self-care 
adherence, and self-care information needs (knowledge) in a sample of adult patients 
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with stable COPD. We hypothesized that participants would report lower levels of 
symptom severity and variability, reduced anxiety and depression scores, better perceived 
self-care ability and perceived self-care adherence, and fewer self-care information needs 
during the intervention period (Days 8 – 21) compared to the pre-intervention period 
(Day 1 – 7).  
The aim of this study was to evaluate the effect of a 14-day, theory-based, 
eHealth, self-care educational intervention on symptom severity and variability scores 
(distress due to cough, chest tightness, distress due to mucous production, dyspnea with 
activity, dyspnea at rest, fatigue, anxiety, and depressive symptoms), perceived self-care 
ability scores, perceived self-care adherence scores (nutrition, physical activity, mental 
health, breathing control, medical management, environment modification, and 
exacerbation planning), and self-care information needs (knowledge scores) with baseline 
measures in a group of stable patients with COPD (N = 20).  
METHODS 
Design 
A quasi-experimental, simple, unbalanced, interrupted time series design (21 
days) was used to determine the effect of an eHealth self-care educational intervention. A 
simple unbalanced design was chosen so that participants served as their own control 
(Days 1 – 7 no intervention, Days 8-21 intervention). Efficacy of the eHealth intervention 
was determined by comparing data from the pre-intervention phase (Days 1-7) to data 
from the intervention period (Days 8-21). Measures of symptom severity and variability, 
perceived self-care adherence, self-care ability, and perceived COPD-specific knowledge 
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needs were collected in a group of stable patients with COPD. Symptom data were 
measured daily to evaluate symptom severity and variability. Measures of anxiety, 
depression, and perceived self-care ability were measured at baseline, Day 8, Day 15 and 
Day 21. Perceived self-care adherence and self-care information needs were measured at 
baseline and on Day 21.  
Sample 
Patients age 40 to 70 years of age who were in the clinic for a routine follow up 
visit with a primary or secondary diagnosis of COPD at a reigonal, community hospital-
affiliated pulmonary clinic in the southern United States, were screened for eligibility. 
Patients were candidates for inclusion if they: 1) had a confirmed diagnosis of COPD 
verified by pulmonary function tests demonstrating moderate to severe disease according 
to GOLD criteria4 (forced expiratory volume in one second [FEV1]/ forced vital capacity 
[FVC] <70% and FEV1 < 80%); 2) had stable disease state defined by absence of an 
exacerbation in last three months; 3) had access to home Wi-Fi internet; 4) could read, 
write and speak English; and 5) had a cell-phone with text messaging capabilities. 
Patients were excluded if they had: 1) presence of symptomatic cardiovascular diseases 
or severe systemic diseases (end-stage liver or renal disease, systemic lupus 
erythematosus or malignancy); 2) impaired eyesight prohibiting accurate visualization of 
tablet font as evidenced by failure to correctly read the tablet home screen application 
list; 3) cognitive impairment as demonstrated by a score of < 2 on the Mini-Cog; or 4) 
low health literacy as evidenced by a score of more than four incorrect responses on the 
Newest Vital Sign instrument.  
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A required sample size of 18 patients with at least 8 complete time points was 
determined by an a priori power analysis estimate. This estimate was based on a one-way 
repeated measures analysis of variance (ANOVA) power estimation with Greenhouse-
Geisser approximation, obtained using nQuery Advisor,96 which assumed there were 8 
time-periods; 8 was the maximum number allowed by the software. With approximately 
18 participants completing the trial, an alpha level of .05, and assuming that successive 
observations from the same participant had a modest correlation of at least 0.3, the power 
of the repeated measures F test to detect a medium effect size should exceed 69% to 
detect changes in outcomes in the time period pre-intervention to the intervention period. 
Two additional participants were added in case of attrition for a final sample size of 20 
participants.   
Measures 
Clinical and sociodemographic variables 
Sociodemographic variables included age, sex, ethnicity, highest education level, 
marital status, employment status, and living situation. Clinical data included height, 
weight, body mass index (BMI), spirometry measures (forced expiratory volume/second 
[FEV1], forced vital capacity [FVC], FEV1/FVC, reference FEV1, reference FVC and 
reference FEV1/FVC), GOLD stage (indicator of severity of disease), number of 
exacerbations in past year, smoking status (packs per day and pack years), and current 
prescribed medications. These data were obtained from medical record review and 
interview.  
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Symptom severity and variability 
Symptom severity and variability were defined as the individual evaluation of the 
degree of intensity and self-perceived change in disease-related symptoms over the 
course of 24 hours for symptoms that included distress due to cough, chest tightness, 
distress due to mucous, dyspnea with activity, dyspnea at rest, and fatigue. A modified 
version of the Daily Symptom Scale (DSS)97 was used to measure symptom severity and 
variability. The 6-item, modified DDS (symptom diary) prompted the participants to rate 
the severity of their symptoms daily. Symptoms were rated on a 100-point visual analog 
scale (VAS) where 0 was absence of a symptom and 100 was the most distressful the 
symptom could be.97 The DDS has been shown to be reliable in patients with similar 
chronic conditions such as cardiovascular disease and heart failure.97 Face validity of the 
modified DDS was confirmed by two pulmonary care experts. Reliability of a 
computerized visual analog scale has been shown to be low to moderate with test-retest 
reliability coefficient of 0.44 – 0.56 and strong convergent validity was demonstrated 
with non-computerized measures.98 
Anxiety and depressive symptoms 
Anxiety is a feeling of worry, nervousness, or unease, typically about an 
imminent event or something with an uncertain outcome.99-101 Depressive symptoms can 
be characterized by feelings of sadness, loss of interest and potential suicidality.102 The 
Hospital Anxiety and Depression Scale (HADS) was used to measure anxiety and 
depression.103 The HADS is a 14-item self-report questionnaire with a 7-item anxiety 
subscale and 7-item depression subscale. The anxiety subscale (HADS-A) reflects a state 
of generalized anxiety and the depression subscale (HADS-D) primarily focuses on the 
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concept of anhedonia commonly experienced in depression. Each question is rated on a 
4-point Likert scale ranging from 0 - absence to 3 - extreme presence. Each subscale can 
be used independently, and scores range from 0-21 for each subscale; a total score out of 
42 is calculated, with higher scores indicating greater levels of anxiety, depression and 
overall psychological distress.103,104 Subscale scores of eight or higher indicate probable 
anxiety and/or depressive symptoms; the HADS has well established validity, reliability 
and diagnostic accuracy for measurement of anxiety and depressive symptoms in patients 
with COPD.103,105-108 
Self-care ability 
Self-care ability was defined as, “the core behavioral and cognitive abilities which 
presumably contribute to sustainable well-being”.109 Self-care ability was measured with 
the Self-Management Ability Scale-Short (SMAS – S),109 a shortened version of the 
SMAS-30.110 It is an 18-item questionnaire that has been used in patients with 
COPD111,112 and other chronic illnesses.111 The SMAS-S total score assesses self-
management ability with items in six sub-scales that include taking initiative, investment 
behavior, variety, multi-functionality, self-efficacy and positive frame of mind.18,110,113 
The taking initiative, investment behavior, and positive frame of mind subscales are 
scored on a 6-point Likert scale, with responses ranging from “never” to “very often”. 
The variety subscale is scored on a 6-point Likert scale with responses ranging from 
“none” to “more than six”. The multi-functionality subscale is scored on a 5-point Likert 
scale with responses ranging from “strongly disagree” to “strongly agree”. The self-
efficacy subscale uses a 5-point Likert scale with responses ranging from “I’m certain 
that I cannot” to “I’m certain I can”. Each sub-scale can be used independently, or all 18 
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questions can be used as a total composite score for self-care ability. The higher the 
score, the better the perceived self-care ability; total scores can range from 18 to 102, and 
there is no established cutoff for this scale.109  The six sub-scales had satisfactory internal 
consistency with Cronbach’s α ranging from 0.69 to 0.77. Construct validity was 
determined using confirmatory factory analysis and hypothesis testing, which yielded 
unidimensionality among each of the subscales, underlying factors measured the 
theoretical constructs of self-care ability, and moderate to high correlation with other 
established measures of self-care and well-being in patients with COPD and other similar 
chronic illnesses.109,111 
Self-care adherence 
Self-care adherence was defined as the extent to which an individual follows the 
self-care recommendation/prescription.114 Self-care adherence was measured with a 
modified version of the Medical Outcome Study Specific Adherence Scale (MOS-
SAS).114 The modified MOS-SAS is an eight-item instrument that assesses adherence for 
each of the seven self-care domains included in this study. These included nutrition and 
diet, physical activity, mental health, breathing control, medical management, 
environment modification, and exacerbation planning. The MOS-SAS evaluates, “How 
often have you done each of the following in the past week?” and each answer is 
measured on a 6-point Likert scale ranging from 0-none of the time, to 5-All of the time. 
Each response is weighted to achieve a range of possible total score of 0–100; all items 
are added then averaged and there are no established cut points for this scale.115 Internal 
consistency for the MOS-SAS ranged from 0.50 to 0.78 in similar chronic disease 
populations who require sustained, lifelong treatment (diabetes, hypertension and heart 
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failure).114 Strong convergent validity has been established in the MOS-SAS with other 
measures of self-care maintenance, self-care management and self-care confidence in 
cardiovascular populations.116 
Self-care information needs 
Self-care information needs were defined as the content required by an individual 
so they can perform self-care.117 Self-care information needs were measured with the 
Lung Information Needs Questionnaire (LINQ).117 The LINQ is a 16-item questionnaire 
developed to assess self-care information needs and COPD knowledge in patients with 
COPD.117 Six domains comprise the LINQ; these include disease knowledge, medicines, 
self-management, smoking, diet, and exercise. Item scores for each domain are added to 
achieve a range of total scores from 0 to 25, with higher scores indicating higher 
information needs. There is no set cutoff for adequacy of informational needs. LINQ total 
score has satisfactory internal consistency with a Cronbach’s α of 0.62.117 Test-retest 
reliability for the total score was good (0.89) and for the six subscales, coefficients 
ranged from 0.66 to 0.98.117 A series of focus groups that included patients with COPD 
and expert healthcare providers supported the content validity of the LINQ in measuring 
information needs in patients with COPD.117  
Intervention 
 The educational intervention contained seven self-guided modules (Table 1.) 
These modules included nutrition and diet, physical activity and exercise, medications, 
breathing control, mental health, environment, and exacerbation planning. The 
educational modules contained material written at a fifth-grade reading level, and 
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imbedded videos. Information included in each module was derived from current self-
care research evidence, 13-15,21,88,118-120 as well as current clinical guidelines from 
organizations that included the Global Initiative for Obstructive Lung Disease (GOLD),4 
American Lung Association,121,122 American Thoracic Society,123 and COPD 
Foundation.124,125 All information was appropriate for individuals at any level of self-care 
proficiency. The educational intervention was housed on a password-protected webpage 
accessible via the study website, accessed by participants using a tablet computer. 
Participants were sent a text message containing a password to access the educational 
intervention eight days after completion of the baseline measures. 
Text messaging to promote adherence  
Participants also received daily text messages from the investigator (Days 2- 21). 
The text messages were sent between 1600 and 1900 every day, to remind the participant 
to complete their daily measures. Each text message was sent individually to maintain 
patient confidentially. Text messages were designed based upon the transtheoretical 
model of Prochaska and colleagues;126 specifically two experiential processes of change 
were targeted, consciousness raising and dramatic relief. Moreover, the text messages 
were targeted and tailored to each participant as outlined by Noar and Harrington.127 Text 
messages were tailored to reinforce targeted behaviors. 
Procedure 
Recruitment and enrollment 
The Baptist Health Lexington and University of Kentucky Medical Institutional 
Review Boards approved this study. Eligible patients were approached by the principal 
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investigator who introduced himself and explained the purpose of the visit upon 
conclusion of the interaction with their pulmonologist. Before enrollment, potential 
participants were screened for mild cognitive impairment using the Mini-Cog©128 and for 
adequate health literacy using the Newest Vital Sign.129 Upon determination of adequate 
health literacy and absence of cognitive impairment, potential participants were asked 
whether they had in-home Wi-Fi and a cell-phone with text messaging capabilities. After 
enrollment, participants were provided with and trained in the use of a tablet-computer 
(Amazon Fire Tablet, 8 gigabytes, 7th generation); training included how to change 
settings (power on/off, volume, charging, accessibility display, Wi-Fi connection), how 
to access and complete a daily symptom diary, how to access the intervention education 
materials, and how to access and complete the other required instruments. Each 
participant was also given written instructions and reminders about when and how to 
access the components of the intervention, and how to contact the principal investigator if 
problems occurred. The tablet-computer was fully unlocked and pre-loaded with a link to 
the website with the intervention.  
Baseline data collection took place in an empty exam room. All measures (Day 1 
– 21) were completed wirelessly using an encrypted data collection system (Research 
Electronic DataCapture [REDCap]), housed behind a firewall at the University of 
Kentucky. Participants were given instructions to connect their tablet computer to their 
home Wi-Fi to ensure accessibility to the website. All data were automatically 
transmitted to REDCap upon completion of each instrument.  
Baseline measures 
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Baseline measures were obtained for symptom severity (DDS for distress due to 
cough, chest tightness, distress due to mucous, dyspnea with activity, dyspnea at rest, and 
fatigue), anxiety and depressive symptoms (HADS), perceived self-care ability (SMAS-
S), perceived self-care adherence (MOS-SAS) and self-care information needs 
(knowledge; LINQ). Participants completed the measures independently or with the help 
of their caregiver; the PI was present for assistance in using the tablet.  
Daily Measures 
Participants were asked to complete a daily symptom diary for the next 20 
consecutive days (Table 2.), at a time of their choosing using the tablet-computer. On the 
website, there was a dedicated daily symptom diary section that contained separate links 
to each respective daily symptom diary. Participants were also informed that there would 
be additional measures of anxiety, depressive symptoms and perceived self-care ability 
on Days 8 and 15; at the end of the study (Day 21) participants repeated all measures.  
Data management  
 Data files were assessed for missing data points and evaluation of data 
distributions in preparation for analysis. Data were screened using frequency distributions 
to evaluate the degree of missing data and the presence of outliers. Missing data were not 
imputed and were left missing. Outliers and leverage points were left unadjusted.   
Data analysis 
 Descriptive statistics including means (standard deviations) and frequencies 
(percent) were used to characterize the sample. Symptom severity was determined for 
each symptom by calculating the mean of symptom ratings pre-intervention, during the 
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intervention period, and across the entire 21-day reporting period for each participant. 
Participants were then categorized into tertiles of low (n = 7), medium (n = 6) or high 
severity (n = 7) for each symptom, based upon the pre-intervention mean (day 1 – 7). 
Symptom variability was determined by calculating the standard deviation of symptom 
ratings pre-intervention, during the intervention period, and across the 21-day reporting 
period for each participant. Based upon the standard deviations calculated in the pre-
intervention period, patients were then categorized into tertiles of low (n = 7), medium (n 
= 6) or high variability (n = 7) for each symptom. 
To determine the effect of the intervention on symptom severity and variability, 
multilevel growth models (MGMs) were constructed using the fixed effects of symptom 
severity group (low, medium high), symptom variability group (low, medium, high), 
intervention status (pre-intervention [Day 1-7] or intervention period [Day 8 – 21]), 
symptom severity group by intervention status, and symptom variability group by 
intervention status; each participant was modeled as a random effect with random 
intercepts and random slopes, using an identity covariance structure, and all estimations 
were made using maximum likelihood estimation. Each growth model was constructed to 
examine symptom severity (distress due to cough, chest tightness, distress due to mucous, 
dyspnea with activity, dyspnea with rest, and fatigue) as a function of time; time was 
centered on zero (Days 0-20). To determine the best fitting model for predicting change 
in symptom severity, a sensitivity analysis analyzing the -2Log Likelihood (-2LL) was 
conducted. Two MGMs were constructed and compared for each symptom; in the first 
model, symptom severity group (low, medium, high) and symptom severity group by 
intervention status were imputed as factors; in the second model, symptom variability 
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group (low, medium, high) and symptom variability group by intervention status were 
imputed as factors.   
To examine the consistency of symptom variability between the pre-intervention 
and intervention periods, a series of McNemar tests were conducted. Symptom variability 
was determined by calculating the standard deviation of symptom scores for each 
symptom, during the pre-intervention period and intervention period; based on the 
standard deviations, participants were placed into low or high symptom variability 
groups. The median standard deviation for each symptom in the pre-intervention period 
was used as a reference point to categorize participants into either high or low variability. 
For each symptom, 10 participants were in each category for the pre-intervention period. 
Then, standard deviations were calculated for the intervention period; values were 
assessed using the median standard deviation from the pre-intervention period. Using the 
median value from the pre-intervention period, participants were then categorized as low 
or high variability for the intervention period. By using the pre-intervention median value 
as a reference point, participants could be evaluated for improvement or worsening of 
standard deviation values for each time period.   
To further examine the effects of the intervention, three repeated measures 
ANOVAs (RM-ANOVA) were conducted to compare mean scores for anxiety, 
depressive symptoms and perceived self-management ability at baseline to measures 
collected on, Day 7, Day 15 and Day 21. Paired sample t-tests were conducted to 
compare mean perceived self-care adherence and perceived self-care information needs 
scores between pre and post intervention. All analyses were performed using SPSS 
version 24 (IBM, Armonk, NY) with an a priori α = 0.05 to indicate significance. 
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RESULTS 
Characteristics of the participants 
 A total of 133 patients were screened for eligibility (Figure 1.). Thirty-seven 
patients met eligibility criteria and were screened for cognitive function and health 
literacy; 17 were excluded. Nine patients were excluded for mild cognitive impairment, 5 
were excluded for inadequate health literacy, 2 were excluded due to an inability to use 
the tablet, and 1 declined the invitation.   
Participants (n = 20) in this study were primarily female (65%), obese (mean BMI 
30.2 + 7.6) Caucasian (90%), and on average 62 + 7 years of age (Table 3.). A majority 
of participants had at least a high school education (60%), were single, widowed, or 
divorced (65%), and were not working due to disability, retirement or lack of 
employment (60%). A majority of the participants were categorized GOLD stage III/IV 
(55%); the mean % predicted FEV1 was 43 + 15%. On average, participants reported 1.5 
+ 1.2 exacerbations requiring hospitalization in the prior year. Eight participants (40%) 
reported they were current smokers, while 50% of participants had quit smoking at some 
point. On average, participants had 6.6 + 4.6 comorbidities and were prescribed 12.9 + 
6.6 daily medications. Participants submitted 401 (95.5%) daily symptom diaries. 
Fourteen participants (74%) completed 100% of their daily diaries. Six participants 
contacted the investigator with issues using the tablet or website. One participant was lost 
to follow up on Day 11 due to an exacerbation requiring hospitalization. 
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Symptom severity and variability 
 Symptoms were measured daily by participants for 21 days using a 0 to 100 VAS 
(Table 2.). At baseline, score for distress due to cough averaged 26.6 + 25.4, for chest 
tightness 28.8 + 24.1, distress due to mucous 27.9 + 22.3, for dyspnea with activity 45.4 
+ 27.8, for dyspnea at rest 25.8 + 26.1, and fatigue 38 + 26.8. Paired sample t-tests were 
used to compare mean values between baseline and intervention scores. There were no 
significant differences in means between the two time periods for the six symptoms.  
  To determine whether symptom severity group or symptom variability group 
were predictors of symptom scores over time, we conducted a sensitivity analysis for 
each MGM. Results from sensitivity analyses revealed that symptom group severity and 
the interaction term of symptom group severity by intervention status produced lower      
-2LL statistics for all six symptoms; thus, all reported MGM results hereafter reflect the 
effects of symptom severity group. MGM analyses determined there was no significant 
effect of the intervention on average symptom severity for any of the six symptoms (p = 
.08 – 0.97). However, there were significant interactions of severity group by intervention 
status for distress due to cough, chest tightness, dyspnea with activity, and fatigue (Table 
4; Figure 2.). Those who were in the medium tertile for distress due to cough at baseline 
demonstrated an increase in reported distress due to cough after the intervention (b = 
10.16, 95% confidence interval [CI] 1.95 – 18.40, t(83) = 2.46, p = .02) compared to 
those in the other two tertiles. Individuals in the medium tertile for severity of chest 
tightness at baseline reported significantly worse severity after the intervention (b = 8.47, 
t[103] = 2.06, p = .04); while those in the high tertile reported significantly lower severity 
of chest tightness after the intervention (b = -8.15, t[113] = -2.03, p = .04). Dyspnea with 
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activity in the medium tertile increased after the intervention (b = 13.18, t[82] = 1.97, p = 
.05). Those who were in the medium tertile for fatigue at baseline also reported a 
significant increase in distress (b = 16.48, t[134] = 3.89, p < .01) compared to the low or 
high tertile.  
 A series of McNemar tests was conducted to examine the consistency between the 
number of participants in high or low variability group between the pre-intervention and 
intervention periods (Table 5.). There were no significant differences in proportion of 
participants categorized as high or low symptom variability from the pre-intervention 
period to the intervention period.  
Comparison of anxiety, depressive symptoms, and perceived self-care ability 
Anxiety, depressive symptoms, and perceived self-care ability scores were 
measured four times (baseline, Day 8, 15 and 21) and compared with RM-ANOVA 
(Table 6.). At baseline, anxiety scores averaged 6.6 + 3.3, depressive symptoms 5.6 + 3.5, 
and perceived self-care ability averaged 58.9 + 12. There were no significant differences 
in scores among the measurement times (p = .62; p = .66; p = .07, respectively).  
Comparison of self-care adherence and self-care information needs 
Perceived self-care adherence and perceived self-care information needs were 
measured at baseline and on Day 21 after completion of the intervention. Baseline mean 
scores were compared to scores obtained on Day 21 with paired t-tests. Perceived self-
care adherence scores increased significantly post intervention (baseline - 58.1 + 19.3, 
post intervention - 67.6 + 12.2, p = .025). Perceived self-care information needs were 
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significantly reduced after the intervention (baseline - 13.7 + 3.1, post intervention - 11.3 
+ 1.8, p = .012).  
DISCUSSION 
 We tested the use an eHealth educational intervention for patients with COPD and 
evaluated its effect on symptom reporting, perceived anxiety and depressive symptoms, 
perceived self-care ability, adherence and needed knowledge. Symptom scores reported 
during the pre-intervention time period were of low to moderate severity, indicating that 
symptom burden for these participants was relatively modest. The most burdensome 
symptom was dyspnea with activity, which is common for participants with moderate to 
severe disease state. Participants in the middle tertile of reported symptom severity at 
baseline perceived that certain symptoms (distress due to cough, chest tightness, dyspnea 
with activity and fatigue) were more severe after the intervention. Those in the highest 
tertile for chest tightness severity reported less burdensome distress during the 
intervention period. There were no significant changes in anxiety, depressive symptoms, 
or perceived self-care ability after the intervention. However, perceived self-care 
adherence scores significantly improved, and self-care information needs were 
significantly reduced after the intervention.  
Our participants interacted with the intervention and were adherent to completion 
of the study instruments. This level of interaction was consistent with previous 
investigators who tested an eHealth intervention and used tailored text messaging to 
promote adherence; adherence to daily symptom diaries and/or intervention activities 
have been reported to be as high as 92% to 99%. 130-132 The engagement of our 
participants with the study may be attributed to a number of factors. First, the daily 
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tailored and targeted text messages were sent to participants to promote completion of 
daily diaries; previous investigators have shown that targeted and tailored text messaged 
aimed to promote desired behaviors resulted in higher completion rates in studies 
assessing adherence in chronic illness.133,134 Second, the participants included in this 
sample were a non-probability sample; thus, they were willing to participate and engage 
upon enrollment. Third, the intervention was built to be engaging by using plain, 
understandable language that was applicable to patients at any level of self-care 
proficiency, and information was presented with a variety of different mediums (text, 
pictures, and videos) to prevent boredom with the intervention. Thus, it is plausible these 
strategies were successful.  
 Using baseline symptom severity measures, participants were placed in tertiles 
that represented low, medium and high severity of each symptom. Multilevel growth 
models were constructed using the symptom severity group (low, medium high), 
intervention status (pre-intervention [Day 1-7] or intervention [Day 8 – 21]), and the 
interaction term of symptom severity group by intervention status as factors. We found 
several significant interactions between symptom severity group and the intervention, 
which indicated the effect of the intervention was dependent on the severity group. Those 
participants who were in the low symptom severity tertile at baseline reported no 
significant changes in perceived symptoms over the 21-day reporting period. Participants 
in the medium tertile group, reported a significant increase in severity of distress due to 
cough (p = .02), chest tightness (p = .04), dyspnea with activity (p = .05), and fatigue (p < 
.01). Participants in the high severity tertile for chest tightness (p = .04) reported a 
significant reduction in this symptom over time. Those participants in the medium 
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severity tertile likely became more aware of their daily symptoms using the daily diary; 
thus, the educational intervention may have helped them evaluate their symptoms 
differently, potentially more accurately. Those participants in the high severity tertile for 
chest tightness reported a less severe symptom during the intervention period; thus, 
participants determined that their distress due to chest tightness was reduced after the 
intervention. Participants either experienced reduced symptom severity or the educational 
intervention altered their evaluation of this symptom. Also, symptoms determined to be 
maximal can only improve. Thus, the change in symptom evaluation was dependent on 
their baseline severity perception of symptoms.  
Previous investigators have examined the effects of a self-care interventions on 
symptom burden over the course of 3, 6 and 12 month follow-up periods.87,120,135 In a 
recent meta-analysis of studies about the effects of self-care interventions on outcomes, 
the investigators concluded that self-care interventions decreased symptom burden by 
6.6% on average.87 However, in a number of the trials included in this meta-analysis, the 
investigators determined that symptom burden remained unchanged or increased after 
implementation of a self-care intervention.136-139 Bourbeau137 and Monninkhof136 found 
no changes in symptom burden at 4 and 12-month follow up. Taylor and colleagues139 
found an increase in symptom burden by 4.7% at six month follow up; McGeoch and 
colleagues found an increase in symptom burden by 4.7% at 12 months post 
intervention.138 These investigators proposed several explanations for this. First, the 
intervention potentially raised awareness of the individual to disease-related symptom 
perception; thus, the reported symptom severity increased over time.138,139 Second, the 
observed symptom severity in previous studies was low to moderate at baseline; this may 
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have limited the ability to detect minute changes in symptoms over time.138 Third, the 
intervention tested may have been ineffective at changing symptom perception.136-139 
140,141  It is possible that the intervention in these studies did not affect symptom severity, 
and reported symptom severity remained unchanged or increased naturally over time.  
Moreover, the measures used may not have been sensitive enough to detect a small 
degree of change in symptoms. Previous investigators have concluded that the severity 
and variability of reported symptom burden varied from 10% to 20%,142,143 which 
indicated that patients may have difficulty conceptualizing symptom experience as a 
number. These investigators also reported symptoms like pain were easier for patients to 
conceptualize as a number when compared to others like fatigue; investigators also 
suggested that patients may not regularly quantify some symptoms making perception of 
a symptom score difficult and insensitive to small changes.142,143  
We proposed that the participants in the middle tertile experienced an increase in 
symptom burden (distress due to cough, chest tightness, dyspnea with activity and 
fatigue) due to a combination of an increased focus on symptom perception, and the 
educational content about symptom monitoring. Previous investigators13,16,144 have 
hypothesized that regular monitoring of symptoms increased perception and sensitivity to 
symptom change and resulted in participants actualizing their symptoms more accurately. 
In our educational intervention, participants were provided education to aid in identifying 
each symptom, and to evaluate the severity at that time; this may have resulted in an 
increased somatic awareness, with more sensitive symptom recognition, evaluation, and 
interpretation. There is also evidence to suggest that those with more severe disease 
might be less sensitive to change in symptom severity, and these individuals might be 
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worse at performing self-management behaviors, such as responding to changes in 
symptom severity.140,144 Bringsvor and colleagues140 proposed that as participant 
symptom burden increased, they reported fewer health-directed behaviors (i.e. symptom 
monitoring, physical activity, relaxation), which then may have negatively influenced 
symptom burden and severity. Previous investigators have examined patient ability to 
recall daily symptoms throughout any given day, day to day or weekly.142,145 
Investigators found that patient report of average symptom experience over a week were 
not as precise as measures of symptom experiences made at their lowest (least 
burdensome) or highest (most burdensome) time point.143 Thus, more frequent evaluation 
may be more precise. In our study, patients in the medium tertile experienced the greatest 
symptom change over time and with daily evaluations were more aware of these changes. 
Our participants in the low and high symptom severity tertiles likely had more consistent 
symptom experiences. However, further studies are necessary to examine the relationship 
between symptom severity and symptom perception in patients with COPD.  
On average, our participants did not meet the HADS cut points for presence of 
anxiety and depressive symptoms. There were no significant changes in anxiety and 
depressive symptom scores between baseline measures and those made on 8, 15 or 21. 
We hypothesized that there would be a decrease in the anxiety scores and decrease or no 
change in depression scores after the intervention. However, our results did not support 
our hypothesis. Some previous investigators also found that self-care interventions had no 
effect on anxiety and depression;92-94 while other investigators reported improvement in 
anxiety and depression scores after an intervention.89,146,147 Investigators who found no 
improvement generally studied participants with low anxiety and depression scores; 
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anxiety and depression subscale scores on average were less than 5.5 for the HADS 
subscales in these participants.92-94  However, those investigators who reported 
improvement in anxiety and depression scores studied participants whose anxiety and 
depressive symptoms scores indicated more severe symptoms.146,147,89 Thus, self-care 
interventions improved anxiety and depression scores when participants were actually 
anxious and had depressive symptoms. Our participants did not report a significant 
degree of anxiety and depressive symptoms at baseline; thus, there was no improvement. 
Clearly, the initial degree of mental distress will influence the degree of change possible.   
At baseline, our participants reported a moderate to high level of perceived self-
care ability. We recruited a convenience sample of patients from a local pulmonary 
clinic. It is likely that those who were interested in and volunteered for participation in 
this study were already engaged in self-care activities to some degree. A majority of our 
participants completed more than a high school education, and we screened for adequate 
health literacy and satisfactory cognitive function; thus, our participants may not 
represent the typical patient with COPD.   
The lack of change in perceived self-care ability could be due to the short time 
period of the study or a lack of sensitivity of the SMAS-S to small change. Self-
management abilities comprise a set of skills that are meant to be practiced, used and 
perfected over time; thus, self-care ability might continue to improve over time and not 
be reflected in these initial scores. A number of prior studies measured indices of self-
care ability such as keeping follow up appointments, completing daily symptom diaries, 
taking prescribed medications, monitoring for changes in symptoms and contacting 
providers for suspected exacerbations.148-150 Investigators for these studies reported no 
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change or a gradual decline of adherence to taking medications as prescribed, smoking 
habits or cessation, attending pulmonary rehabilitation, and reporting increasing symptom 
severity to practitioners.148-150 Researchers postulated that this decline in self-care 
behaviors could be due to a loss of interest in self-care, increased complexity in 
prescribed treatment regimen, and poor quality of care from providers.24,149 Additionally, 
Cramm and Nieboer 151 reported that higher perceived quality of care from providers and 
productive patient-professional interactions were significant predictors of higher 
perceived self-care ability scores in patients with COPD. However, previous investigators 
who examined self-care ability implemented a high dose of their intervention through 
repeated, structured interventions over the course of days to weeks; while we designed 
our intervention to be less structured and as a smaller dose. Thus, it is likely that our short 
time frame and low dose were not adequate to produce change. It is also possible that 
since perceived self-care ability was already moderately high in our participants, it is 
likely the intervention did not provide a dose adequate to produce an improvement and a 
probable ceiling effect was observed.  
Our participants did demonstrate significant improvement in perceived self-care 
adherence and reduction in perceived self-care information needs. On average, our 
participants improved their perceived self-care adherence by 9.5% and reduced their 
perceived self-care information needs by 9.6% after the two-week intervention period. 
This is consistent with previous investigators who examined the impact of self-care 
interventions on adherence and self-care knowledge.152,153 Leiva-Fernandeza and 
colleagues152 tested a multidimensional self-care intervention and demonstrated that the 
experimental group improved perceived adherence by 30.5% compared to control. Smit 
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and colleagues,153 assessed treatment adherence to smoking cessation behaviors (a 
component of self-care); participants were 85% to 99% more likely to abstain from 
smoking at one week and at 6 month follow up. Although the length of our intervention 
was brief (two weeks), we observed improvement in perceived self-care adherence and 
reduction in self-care information needs. Results from prior studies indicated that 
multidimensional self-care interventions were effective at improving treatment 
adherence, reduced perceived information needs, and led to sustained behavior change in 
patients with COPD.152,153 Our study is similar to previous investigators in that we 
implemented a multifaceted and tailored intervention. However, we used an eHealth 
mode of delivery. Our results supported this strategy and demonstrated that participants 
actively engaged, learned and increased perceived adherence to self-care behaviors with a 
remote, electronic intervention that required minimal provider assistance. Future studies 
are needed to examine the long-term impact of self-care adherence and information needs 
using eHealth educational interventions in patients with COPD. 
Limitations  
 There are several limitations of this study. The sample for this study was small 
and limited power to detect differences for some of our analyses. Although we were 
adequately powered for our MGM analyses, the measures may not have had sufficient 
sensitivity to detect change. This was a non-probability sample of relatively well 
educated participants with adequate health literacy and normal cognitive function. 
Second, self-report instruments were used in this study, which introduced the potential 
for social desirability and response bias. However, the variables we measured were 
subjective; thus, self-report was the only appropriate way to measure them.154 Third, the 
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intervention exposure was of short duration because this was the initial step in the 
evaluation of dose response to this intervention.  In addition, our participants did not 
report anxiety or depressive symptoms using the HADS. This instrument might not have 
been sensitive in this group of individuals; however, the HADs has been used in other 
samples of patients with COPD.89,93-95,146,147 Also, our sample of participants had a high 
level of perceived self-care ability; thus, we were unable to determine whether the 
intervention can produce a change in people with low perceived self-care ability.   
 Conclusion  
These participants had a low to moderate degree of symptom burden; dyspnea 
with exertion was the symptom with greatest severity. Our theory-based, self-care 
educational intervention delivery via electronic platform produced change in perception 
of distress due to cough, chest tightness, dyspnea with activity and fatigue in participants 
with a moderate degree of symptom burden; for those with high symptom burden for 
chest tightness, there was a significant decrease in reported symptom. The intervention 
produced an improvement in perceived self-care by nearly 10% and reduced perceived 
knowledge needs by almost 10%; thus, further testing of this intervention is supported. 
This study served as a preliminary study to support that patients with moderate to severe 
COPD have the ability to routinely record their symptoms remotely and participate in 
self-guided self-care education modules. 
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Table 4.1. Description of the seven educational components included in the 
intervention 
Self-Care 
Component 
Primary Content Covered Delivery/ 
Teaching 
Style Used 
Nutrition/Diet 1. Caloric intake and weight management 
2. Macronutrients 
3. Meal timing and portions 
4. Water consumption  
5. Vitamins, minerals, and dietary 
supplements 
Print, 
Pictures, 
Informational 
Videos,  
Physical 
Activity and 
Exercise 
1. Physical activity promotion 
2. Recommended exercises for people 
with COPD 
3. Amount of exercise per day/week 
4. Breathing control while exercising 
5. Developing prolonged exercise habits 
Print, 
Pictures, 
Videos, 
Interactive 
Videos 
Medications 1. Compiling an accurate list of 
medications 
2. Knowing the timing and dosing of daily 
medications 
3. Pharmacological and non-
pharmacologic ways to manage acute 
symptom onset  
4. Establishing the most common side 
effects of different medications 
5. Establishing an action plan for when 
symptoms need acute treatment 
Print, 
Pictures, 
Videos, 
Interactive 
Videos 
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Breathing 
Control 
1. Pursed lip breathing  
2. Diaphragmatic/belly breathing 
3. Utilizing rest to prevent dyspnea 
4. Postural positioning for optimal 
breathing 
5. Using relaxation techniques to combat 
the anxiety-dyspnea cycle 
Print, 
Pictures, 
Videos, 
Interactive 
Videos 
Mental Health 1. Identification of life stressors 
2. Developing a plan to combat common 
life stressors 
3. Utilization of breathing techniques to 
reduce anxiety/dyspnea 
4. Non-traditional ways to cope with 
anxiety: meditation, mindfulness, muscle 
relaxation, biofeedback, and distraction 
therapy 
5. Identifying anxiety and depressive 
symptoms 
Print, 
Pictures, 
Videos, 
Interactive 
Videos 
Environmental 
Modification 
1. Smoking cessation/avoiding lung 
irritants 
2. Involvement of caregiver/significant 
other/friend/family with medical care 
3. Promoting social interaction 
4. Energy conservation 
5. Modifying living arrangements 
Print, 
Pictures, 
Videos 
Exacerbation 
Planning 
1. Developing an action plan 
2. Establishing symptom norms and 
knowing when to seek help 
3. Identifying where is most appropriate to 
seek medical treatment 
Print and 
Pictures 
74 
Table 4.1, Cont.  
 4. Identifying early warning signs of 
worsening symptoms 
      5. Medication uses when symptoms become                           
 worse 
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Table 4.2. Timing of variable measurements 
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Table 4.3 Characteristics of participants 
Characteristic Total Sample 
N = 20 
Age in years 62 + 7 
Female 13 (65%) 
Ethnicity 
   Caucasian 
 
18 (90%) 
Highest Education Level 
   Less than high school 
   High School Graduate or above 
 
8 (40%) 
12 (60%) 
Marital Status 
   Single 
   Married 
   Widowed/Divorced 
 
8 (40%) 
7 (35%) 
5 (25%) 
Smoking Status 
   Current Smoker 
   Quit Smoking 
   Never Smoker 
 
8 (40%) 
10 (50%) 
2 (10%) 
Employment Status 
   Employed 
   Disabled/Sick Leave 
   Retired/ Unemployed 
 
8 (40%) 
6 (30%) 
6 (30%) 
Live Alone 6 (30%) 
GOLD Stage  
   II 
   III 
   IV 
 
9 (45%) 
5 (25%) 
6 (30%) 
BMI in kg/m2 30.2 + 7.6 
Number of Comorbidities 6.6 + 4.6 
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Number of Exacerbations in 
Previous Year 
1.5 + 1.2 
Number of Medications Prescribed 12.9 + 6.6 
FEV1  in liters per second 1.17 + .43 
% predicted FEV1  43 + 14.9 
FVC in liters 2.5 + .73 
FEV1/FVC 48 + 13.4 
Values are mean + SD or f (%) 
Abbreviations: GOLD, Global Initiative for Obstructive Lung 
Disease Stage; BMI, body mass index; FEV1, forced expiratory 
volume in one second; FVC, forced vital capacity 
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Table 4.4. Comparison of symptom severity at baseline with intervention values by 
tertiles 
Symptom Severity 
Group 
Mean severity rating 
pre-intervention (Day 0 
– 6) 
M + SE 
Mean severity 
rating intervention  
(Day 7 – 20) 
M + SE 
P value 
Distress due to Cough a    
Low 7.16 + 3.13 6.90 + 2.97 .82 
Medium 29.96 + 4.93 40.03 + 4.70 .02 
High 63.76 + 4.02 60.71 + 3.90 .24 
Distress due to Mucous b    
Low  7.46 + 4.79 11.79 + 4.55 .15 
Medium 33.44 + 4.36 33.12 + 4.13 .79 
High 55.84 + 5.28 55.51 + 5.26 .76 
Chest Tightness c    
Low 7.42 + 3.36 6.40 + 3.13 .43 
Medium 35.41 + 4.50 43.30 + 4.20 .04 
High 60.48 + 4.10 52.37 + 3.92 .05 
Dyspnea with activity d    
Low 8.92 + 4.28 9.71 + 3.91 .74 
Medium 51.18 + 5.23 63.96 + 4.79 .05 
High 66.64 + 3.29 66.95 + 3.07 .95 
Dyspnea with rest e    
Low 5.84 + 3.14 9.47 + 2.96 .10 
Medium 38.02 + 3.74 39.98 + 3.53 .42 
High 73.52 + 5.71 68.07 + 5.65 .93 
Fatigue f    
Low 9.32 + 4.52 15.93 + 4.06 .06 
Medium 40.12 + 4.46 56.64 + 4.17 < .01 
High 70.24 + 4.82 66.70 + 4.38 .30 
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Table 4.4, Cont.  
Analyses based on primary outcome variable (symptom severity scores [range 0 – 100] 
aFixed effects: intervention status F(1,383.34) = 3.03, p = .08; severity group 
F(2,20.44) = 67.35, p < .01; intervention status*severity group F(2, 383.38) = 7.71, p < 
.01;  
bFixed effects: intervention status F(1,380.75) = 1.09, p = .34; severity group 
F(2,20.23) = 23.30, p < .01; intervention status*severity group F(2, 381.66) = . 62, p = 
.43;  
cFixed effects: intervention status F(1,384.24) = 0.08, p = .78; severity group 
F(2,20.66) = 55.14, p < .01; intervention status*severity group F(2, 384.07) = 8.71, p < 
.01;  
dFixed effects: intervention status F(1,382.63) = 7.08, p < .01; severity group 
F(2,20.82) = 73.35, p < .01; intervention status*severity group F(2, 382.93) = 4.62, p = 
.01;  
eFixed effects: intervention status F(1,388.54) = .01, p = .97; severity group F(2,20.26) 
= 61.05, p < .01; intervention status*severity group F(2, 385.84) = 2.43, p = .09;  
fFixed effects: intervention status F(1,384.47) = 10.90, p < .01; severity group 
F(2,20.87) = 48.26, p < .01; intervention status*severity group F(2, 384.45) = 8.37, p < 
.01 
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Table 4.5. Comparison of symptom variability at baseline and intervention 
Symptom Pre-Intervention Intervention 
Period 
P value 
Distress due to Cough 10 (50%) 10 (50%) 1.00 
Distress due to Mucous 10 (50%) 6 (30%) .22 
Chest Tightness 10 (50%) 5 (25%) .13 
Dyspnea with Activity 10 (50%) 6 (30%) .22 
Dyspnea with Rest 10 (50%) 12 (60%) .69 
Fatigue 10 (50%) 6 (30%) .22 
Values are frequency (%) 
The proportion of participants in the high symptom variability category pre-
intervention were compared to the intervention period using McNemar tests. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
81 
Table 4.6. Comparison of mean scores for symptoms, anxiety, depressive symptoms, 
perceived self-care ability, adherence and information needs (n = 19) 
Variable Baseline Day 8 Day 15 Day 21 
P 
Value 
HADS -  anxiety 
[0 – 21] 
6.6 + 3.3 6.8 + 3.9 6.2 + 4.1 6.3 + 4.3 .62 
HADS – 
depression [0 – 21] 
5.6 + 3.5 5.8 + 3.1 5.5 + 3.3 6.1 + 3.4 .66 
Perceived Self-
care Ability 
(SMAS-18) [12 – 
84] 
58.9 + 12 55.5 + 13.5 54.3 + 14.5 57.4 + 14.5 .07 
Self-care 
Adherence [0 – 
100] 
58.1 + 19.3 - - 67.6 + 12.2 .03 
Self-care 
Information Needs 
[0 – 25] 
13.7 + 3.1 - - 11.3 + 1.8 .01 
Symptom variable Pre-intervention period Intervention-period  
Distress Due to 
Cough 
26.6 + 25.4 27.8 + 26.2 .59 
Chest Tightness  28.8 + 24.1 28.1 + 24.4 .79 
Distress due to 
Phlegm 
27.9 + 22.3 29.3 + 23.3 .68 
Dyspnea with 
Activity 
45.4 + 27.8 48 + 28.9 .27 
Dyspnea at Rest 25.8 + 26.1 27.4 + 24.3 .48 
Fatigue 38 + 26.8 44.8 + 27.2 .08 
Values are mean + SD; bracketed information [] are ranges of total possible scores 
Comparisons were performed with paired t-tests, or repeated measures analysis of 
variance, based on the number of repeated measures. 
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Table 4.6, Cont. 
Abbreviations: HADS, Hospital Anxiety and Depression Scale; SMAS-18, Self-
management Ability Scale – 18-item version 
 
  
83 
 
Figure 4.1. Screening and Enrollment Flow Diagram 
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Figure 4.2. Trends in symptom severity over time, stratified by symptom severity 
group (low, medium, high).  
 
Distress due to Cough 
Chest Tightness Dyspnea with Activity 
Fatigue Dyspnea with Rest 
Distress due to Mucous  
p = .82 
p = .02 
p = .24 p = .76 
p = .79 
p = .15 
p = .05 
p = .04 
p = .43 
p = .95 
p = .05 
p = .74 
p = .93 
p = .42 
p = .10 
p = .30 
p = .01 
p = .06 
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CHAPTER FIVE 
Conclusions 
Summary of findings 
The purpose of this dissertation was to evaluate the relationship between 
biological, psychosocial and behavioral self-care attributes and outcomes in individuals 
with COPD. COPD affects millions of people worldwide, and as COPD progresses, 
symptoms become more severe, physical and psychological responses are elicited, and 
risk for hospitalization increases.1 As the prevalence and burden of COPD increases, 
patients are taught and expected to perform a variety of self-care activities to maintain 
physical, mental, and psychosocial homeostasis. Although research evidence exists to 
support the effectiveness of self-care in the reduction of the risk for hospitalization, 
increase in health-related quality of life, and significant decreases in symptoms such as 
dyspnea, anxiety and depressive symptoms,15,18,21,88 the relationship between self-care 
behaviors, symptom burden and perceived self-care ability remain unclear.   
The first manuscript was a report of a secondary data analysis in which we 
explored the predictive power of forced vital capacity (FVC), forced expiratory volume 
in one second (FEV1), and the ratio between the two (FEV1/FVC) for event-free survival 
in patients with heart failure and airflow limitation. The second manuscript was a report 
of a psychometric evaluation of the Multidimensional Scale of Perceived Social Support 
(MSPSS) in a sample of patients with comorbid COPD and heart failure. The third 
manuscript reported the testing of a self-care educational intervention using an eHealth 
platform, in which symptoms, anxiety, depressive symptoms, perceived self-care ability, 
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perceive self-care adherence and self-care information needs (knowledge) were evaluated 
before and after the intervention.  
Patients with comorbid COPD and heart failure share numerous commonalities 
including predisposing risk factors, symptom presentation, and periodic disease 
exacerbations. Approximately one-third to 40% of patients diagnosed with heart failure 
are also diagnosed COPD.30,31 Although airflow limitation may be present in a significant 
proportion of patients with heart failure, the relationship between airflow limitation and 
combined all-cause hospitalization/mortality had not been explored in patients with heart 
failure and suspected airflow limitation. In the second chapter, we presented a secondary 
data analysis examining the predictive power of spirometry measures (forced vital 
capacity [FVC], forced expiratory volume in one second [FEV1], and the ratio between 
the two [FEV1/FVC]) for event free survival in patients with a primary diagnosis of heart 
failure. Airflow limitation resulted in a 2.2 times greater risk of hospitalization or death 
compared to those patients without airflow limitation. Individuals who were in NYHA 
functional class III/IV were 73% more likely to be hospitalized or die compared to those 
with less severe disease (NYHA functional class I/II), and patients who had never 
smoked were 62% less likely to have a health-related hospitalization/death. Regularly 
measuring airflow limitation in patients with comorbid heart failure and COPD may 
permit more effective management and provide an opportunity to reduce 
hospitalization/mortality in these patients. Future research studies should focus on the 
development and testing of tailored self-care strategies for individuals with comorbid 
diseases.   
87 
Due to the high symptom burden, complex treatment regimens, and decrease in 
functional capacity, patients with COPD may have caregivers, friends, family or 
significant others assist them to manage their disease, symptoms, and prescribed 
treatments. Chapter Three contains a report of a psychometric evaluation of the 
Multidimensional Scale of Perceived Social Support (MSPSS) in patients with comorbid 
COPD and heart failure. The MSPSS was evaluated for internal consistency, split-half 
reliability, construct validity with factor analysis, and hypothesis testing. Findings 
revealed that in patients with comorbid COPD and heart failure, the MSPSS had excellent 
internal consistency, and good split-half reliability. Factor analysis yielded a 3-factor 
solution with instrument items loading appropriately on each of the three subscales of the 
MSPSS. Hypothesis testing further supported construct validity; perceived social support 
scores predicted higher self-care management scores. We concluded the MSPSS was a 
valid and reliable instrument to measure perceived social support in patients with 
comorbid COPD and heart failure. Further research is warranted to examine the impact of 
perceived social support on key outcomes in individuals with COPD and heart failure, 
such as symptom burden, anxiety, depression, self-care ability, and survival. 
There is a lack of evidence about the immediate effects of self-care interventions 
on key outcomes, particularly symptom burden (severity of distress due to cough, chest 
tightness, distress due to mucous, dyspnea with activity, dyspnea at rest, fatigue, anxiety, 
and depressive symptoms). The third paper in this dissertation reported a test of a theory-
based, multidimensional, self-care educational intervention on key outcomes in patients 
with COPD. Intervention components included modules about diet, breathing control, 
mental health, physical activity, medications, environment modification and 
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exacerbations; outcome measures were symptoms (distress due to cough, chest tightness, 
distress due to mucous, dyspnea, fatigue, anxiety and depressive symptoms) perceived 
self-care ability, and self-care information needs (knowledge). Growth models were 
constructed to examine the impact of the intervention on symptom severity and 
variability. Repeated measures analysis of variance examined the effect of the 
intervention on anxiety and depressive symptoms, and perceived self-care ability at the 
end of week 1, 2 and the conclusion of the reporting period. Paired t-tests determined the 
effect of the intervention on perceived self-care adherence and self-care information 
needs (knowledge). This intervention resulted in significant change in symptom severity 
evaluation in patients categorized as having medium symptom severity for distress due to 
cough, chest tightness, dyspnea with activity and fatigue; these symptoms were perceived 
as more severe in the intervention period. Anxiety, depressive symptoms and perceived 
self-care ability were unchanged; however, perceived self-care adherence scores 
improved, and knowledge needs were significantly reduced after the intervention.  
Our findings described the immediate impact of a self-care intervention on 
symptom evaluation, as well as perceived self-care adherence and self-care information 
needs (knowledge). Future studies will provide additional data. First, future studies are 
needed to examine the hypothesis that baseline symptom severity has an impact on the 
effect of self-care interventions. Second, further exploration is warranted regarding the 
effect of tailored self-care interventions on anxiety and depressive symptoms in patient 
with COPD. Since our patients were not exhibiting substantial anxiety or depressive 
symptoms at baseline, it is difficult to draw conclusions regarding the effects of the 
intervention on these outcomes. Third, longitduinal studies with time periods up to one 
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year are needed to evaluate the long term effects of self-care interventions on variables 
such as symptom burden, self-care adherence and information needs using eHealth 
educational interventions in patients with COPD. Furthermore, an increased dose of the 
intervention, addition of a control group, and accounting for the time of year (to account 
for expected seasonal fluctuations) are warranted.  
Impact of dissertation on the state of the science 
 There are few investigators who have examined the effect of a self-care 
intervention on symptoms such as distress due to cough, chest tightness, distress due to 
mucous and fatigue in patients with COPD. Although researchers have established that 
symptom burden was a significant clinical problems in patients with COPD, self-care 
interventions have not been found to improve symptom perception with the exception of 
dyspnea, anxiety and depressive symptoms.19,120 Although investigators have tested 
interventions to improve self-care in patients with COPD, the most recent American 
Thoracic Society and GOLD guidelines for management of stable COPD provided 
minimal recommendations for self-care behaviors.4,155 Current recommendations 
included taking medications as prescribed, smoking cessation, and reporting increased 
symptom severity or potential exacerbations to providers; future research is needed to 
establish evidence-based guidelines and recommendations for other aspects of self-care 
including, diet/nutrition, mental health, physical activity, and environment modification.  
 In this dissertation, my research findings have: 1) identified the influence of 
comorbid disease (heart failure and COPD) on key outcomes, hospitalization and 
survival; 2) tested the psychometric rigor of a measure of perceived social support in 
patients with comorbid chronic conditions (COPD and heart failure); 3) concluded 
90 
perceived social support is a significant predictor of perceived self-care management 
ability in patients with comorbid COPD and heart failure; 4) demonstrated that an 
electronic, educational intervention  altered the perception of symptom severity in subsets 
of patients and increased self-care adherence and knowledge in patients with COPD; 5) 
demonstrated that patients with COPD recorded daily symptom evaluation with high 
rates of adherence; 6) supported that this short dose of an intervention improved 
perceived self-care adherence and reduced knowledge needs; and 7) demonstrated that 
this selected sample of patients with COPD were able to interact with the intervention, 
given the short exposure, and received benefit from the intervention. 
There are limitations of this dissertation. Two of the three manuscripts reported 
retrospective data analyses; thus, we could not control for other variables that may have 
influenced the evaluated patient outcomes. These secondary analyses were also limited in 
terms of data collected; for the survival analyses, there were limited number of 
participants with confirmed spirometry values indicating presence of airflow limitation 
and COPD. For the third study, the sample was small and had limited power to detect 
differences for some of our analyses. Although we were adequately powered for our 
growth curve analyses, the measures may not have had sufficient sensitivity to detect 
change. Furthermore, all of the instruments used in this study were self-report, which 
introduced the potential for social desirability and response bias. However, the variables 
we measured were subjective; thus, self-report is the only suitable way to measure 
them.154 Future objective measures of self-care adherence, medication adherence, 
physical activity, and nutritional intake should be used to compare actual to perceived 
variables.   
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Further systematic research studies are needed to determine the most effective 
strategies to improve self-care in this population. Future studies should aim to identify 
key health behaviors that would promote optimal health for patients with COPD and test 
those behaviors for improvements in outcomes. Moreover, subsequent studies should aim 
to examine the validity of self-reported symptom burden measures, especially for 
symptoms such as distress due to cough, chest tightness, distress due to mucous and 
fatigue. Finally, investigators should focus on exploring the short-term and long-term 
impact of self-care interventions on symptom burden, anxiety, depression, sustained 
adherence, morbidity and mortality. 
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